3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHL
&/,1,&$/678'<35272&2/
$Q2SHQODEHO5DQGRPL]HG)RXUSHULRG &URVVRYHU6WXG\LQ7ZR3DQHOVRI+HDOWK\
$GXOW3DUWLFLSDQWVWR$VVHVVWKH5HODWLYH%LRDYDLODELOLW\)RRG (IIHFWDQG
'RVHGHSHQGHQFHRI6LQJOH'RVH, PPHGLDWH5HOHDVHDQG6LQJOHGRV H'LVSHUVLEOH
)RUPXODWLRQVRI3UHWRPDQLG
35272&2/180%(5
3D&/
9(56,21'$7(
'HF

&21),'(17,$/,7<67$7(0(17
7KHFRQILGHQWLDOLQIRUPDWLRQLQWKLVGRFXPHQWLVSURYLGHGWR\R XDVDQ,QYHVWLJDWRURU
FRQVXOWDQWIRUUHYLHZE\\RX\RXUVWDIIDQGWKHDSSOLFDEOH,Q VWLWXWLRQDO5HYLHZ
%RDUG,QGHSHQGHQW(WKLFV&RPPLWWHH<RXUDFFHSWDQFHRIWKLVGRF XPHQWFRQVWLWXWHV
DJUHHPHQWWKDW\RXZLOOQRWGLVFORVHWKHLQIRUPDWLRQKHUHLQWR RWKHUVZLWKRXWZULWWHQ
DXWKRUL]DWLRQIURP:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLF HV//&H[FHSWWRWKH
H[WHQWQHFHVVDU\WRREWDLQLQIRUPHGFRQVHQWIURPSHUVRQVZKRSD UWLFLSDWHDVVXEMHFWVLQ
WKLVVWXG\Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 3
&%'%%"(	( ((

	

Na-R;MH57;Ha/5M:OKC^;:a%OXS	R;SCO:a !SOTTOZ;Sa0VX:]aCMa1[Oa .5M;HTaOU';5HVB]a:XHVa
0X7F;8VTaVOaTT;TTaVB;a/;H5VDZ;a CO5Z5CH57CHCV]a%OO:a$@;8Va5M :a"OT;
:;R;M:;M8;aO<a
0CMAH;:OT;a(KK;:C5V;
S;H;5T;a 5M:a0CMAH;
:OT;a"CTR;STC7H;a%OSKXH5VCOMTa O<a.S;VOK5MC:a
.SOVO8OHa+XK7;Sa
0ROMTOSa
0ROMTOSa!OMV58Va
*;:D85Ha-=>E8;Sa.5
!)
a
&HO75HaHIC5M8;a?QSa1 a "SYAa";Z;HORK ;MVa1 aHHD5M8;a
%S5M8;Ta.5RR5Ta
1 aHHC5M8;a
a25JHa0VS;;VaVBa%HOOSa
+;[a3OSGa+3aa
.BOM;aa

a
 
0CAM5VXS;aÇ g¤{µÇ ^p|ÇU·º¤Çc{³³p¼Çg¤¨f{p»­¤osÄ|¶|Å¾x²¤Ç
j¥Çk¢9Ç -Ov
7: ;$)ÇPgkÇ
F4*)S)*4H7ZF-GFJ2Ç nI/Ç ÇQ554)6$Ç
MWOMCOa1OM]a)OK75S:Ca*#a
1 aHHC5M8;a
a25HHa0VS;;Va%HOOSa
,;[a3OSGa+3aa
.BOM;a

a
%5\a

a


0CAM5VXS;ah«·Ç_q }ÆÇGªÀ­¤Ç[­ Ás¬ÇheW.<r³³°Ä|¾¸¼ybM{¤½Ç
h¤Çl¡{ =Ç,	|w8XÇ ®Ç(&>"(Ç dhlÇ
\T`KR\N42%Y!4)048"RSaK1LÇ"5V;a
"5V;a
.SCM8CR5Ha(MZ;TVCA5VOSa !]MVBC5aa45KOS5a
(
"# $(2OSH:[C:;a!HCMC85Ha1SC5HTa$5SH]a .B5T;a0;SZC8;Ta))!a
a,
$a)OORaa0XCV;a a
05MaMVOMCOa1;\5Taa
1;H;RBOM;a
a
%5\a
a 	
h¤u©Ç^s}?ÇV}¯¹}ÇF¿~~Ç
i¤¤f~s»±¤@s´·±Ä~Â»z­tÃ ~¦¾Ç
g§¤Çm£Ç
O|D
 8X+A BÇV]lÇ
68%*K'$42L4F4E#43CUÇ
0CAM5VXS;a

	
 
	 
 

(
(!!("5V;a
_6LP96
`a

(((Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 4
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHLLL35272&2/6<1236,6
1DPHRI6SRQVRU&RPSDQ\ 7%$OOLDQFH 
1DPHRIWHVWSURGXFW 3UHWRPDQLG 
1DPHRIDFWLYHLQJUHGLHQW 3UHWRPDQLG 
7LWOHRIVWXG\ $Q2SHQODEHO5DQGRPL]HG)RXUSHULRG&URVVRYHU6WXG\LQ7ZR3 DQHOVRI+HDOWK\
$GXOW3DUWLFLSDQWVWR$VVHVVWKH5HODWLYH%LRDYDL ODELOLW\)RRG(IIHFWDQG'RVHGHSHQGHQFHRI
6LQJOH'RVH,PPHGLDWH5HOHDVHDQG6LQJOHGRVH'LVSHUVLEOH)RUPX ODWLRQVRI3UHWRPDQLG 
3ULQFLSDO,QYHVWLJDWRU &\QWKLD$=DPRUD0' 
6WXG\&HQWHU
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//& 
1(/RRS 6XLWH
6DQ$QWRQLR7H[DV 
6WXG\SHULRG PD[LPXPGXUDWLRQIURPVFUHHQLQJWR
VWXG\H[LWGD\V 3KDVHRIGHYHORSPHQW 

'XUDWLRQRIWUHDWPHQW
GD\VZLWKDIROORZXSYLVLW GD\VIROORZLQJWKHODVW
3.VDPSOHLQWKHODVWWUHDWPHQWVHVVL RQRUDIWHUGURS RXW
)RXUVLQJOHGRVHWUHDWPHQWVZLOOEHDGPLQLVWHUHG WRHDFK
VXEMHFWZLWKDGD\ZDVKRXWSHULRGEHWZHHQHDFKGRVH1XPEHURIVLWHVHQUROOLQJVXEMHFWV 
1XPEHURIHYDOXDEOHVXEMHFWV SODQQHG SDQHOVRISDUWLFLSDQWVHDFK
'LDJQRVLVDQGPDLQFULWHULDIRULQFOXVLRQ
9ROXQWHHUVZLOOEHKHDOWK\DGXOWPDOHVRUIHPDOHVWR\HD UVRIDJHLQFOXVLYH
2EMHFWLYHV
3ULPDU\2EMHFWLYH
x7RDVVHVVWKHUHODWLYHELRDYDLODELOLW\RIWKHVLQJOHGRVHGLVSH UVLEOHIRUPXODWLRQLQWHQGHGIRU
SHGLDWULFWUHDWPHQWXVLQJWKHPJVLQJOHGRVHLPPHGLDWH UHOHDVHIRUPXODWLRQDVWKHUHIHUHQFH
6HFRQGDU\2EMHFWL YHV
x7RGHWHUPLQHWKHIRRGHIIHFWIRUHDFKRIWKHIRUPXODWLRQV
x7RDVVHVVWKHHIIHFWRIGRVHRQWKHELRDYDLODELOLW\RIWKHGLVS HUVLEOHSHGLDW ULFIRUPXODWLRQXQGHUIHG
DQGIDVWHGFRQGLWLRQV
x7RHYDOXDWHWKHWDVWHSHUFHSWLRQRIWKHGLVSHUVLEOHSHGLDWULFI RUPXODWLRQXQGHUIHGDQGIDVWHG
FRQGLWLRQV
x7RHYDOXDWHWKHVKRUWWHUPVDIH W\DQGWROHUDELOLW\IRUHDFKRIWKHIRUPXODWLRQVXQGHUIHGDQG IDVWHG
FRQGLWLRQV
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 5
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHLY6WXG\GHVLJQRYHUYLHZ
7KLVLVDVLQJOHGRVHRSHQODEHOUDQGRPL]HGIRXUSHULRGIRXUWUHDWPHQ WFURVVRYHUVWXG\LQKHDOW K\
DGXOWVXEMHFWV (DFKSDQHORIVXEMHFWVZLOOEHUDQGRPL]HGDFFRUGLQJWRWKH VDPHVHTXHQFH
SHULRG:LOOLDPVGHVLJQLQZKLFKHDFKSDUWLFLSDQWZLOOUHFHLYH IRXUVLQJOH GRVHWUHDWPHQWV6XEMHF WVLQ
3DQHOZLOOUHFHLYHDOOWUHDWPH QWVDIWHUFRQVXPLQJDQ)'$VWDQGDUGKLJKIDWKLJKFDORULH EUHDNIDVW
IROORZLQJDQRYHUQLJKWIDVWRIDWOHDVWKRXUV6XEMHFWVLQ3 DQHOZLOOUHFHLYHDOOWUHDWPHQWVGLUHFWO\
IROORZLQJDQRYHUQLJKWIDVWRIDWOHDVW KRXUV7KHWZRSDQHOVZLOOEHLQYHVWLJDWHGFRQFXUUHQWO\
,QYHVWLJDWLRQDOSURGXFWVGRVDJHVDQGPRGHRIDGPLQLVWUDWLRQ
7UHDWPHQW$UHIHUHQFH PJJLYHQDVDVLQJOHPJWDEOH WXVLQJWKHLPPHGLDWHUHOHDVH
IRUPXODWLRQRUDOO\DGPLQLVWHUHG
7UHDWPHQW%WHVW PJJLYHQDVIRXUPJWDEOHWVXVLQJ WKHGLVSHUVL EOHSHGLDWULF
IRUPXODWLRQRUDOO\DGPLQLVWHUHG
7UHDWPHQW&WHVW VLQJOHPJGLVSHUVLEOHWDEOHWRUDOO\DG PLQLVWHUHG
7UHDWPHQW'WHVW VLQJOHPJGLVSHUVLEOHWDEOHWRUDOO\DG PLQLVWHUHG
6XEMHFWVLQ 3DQHOZLOOEHDGPLQLVWHUHGHDFKWUHDWPHQWDERYHDIWHUDKR XURYHUQLJKWIDVWDQGD
KLJKIDWKLJKFDORULHEUHDNIDVW6XEMHFWVLQ 3DQHOZLOOEHDGPLQLVWHUHGHDFKWUHDWPHQWDERYHDIWHUD
KRXURYHUQLJKWIDVW
&ULWHULDIRUHYDOXDWLRQ
3KDUPDFRNLQHWLFV 
)XOOSKDUPDFRNLQHWLFSURILOHVRISUHWRPDQLGZLOOEHGHWHUPLQHGXSWR KRXUVDIWHUHDFKLQWDNHRI
SUHWRPDQLG%ORRGVDPSOHVIRUDQDO\VLVRISUHWRPDQLGFRQFHQWUDW LRQVZLOOEHGUDZQMXVWEHIRUHGUXJ
LQWDNHSUH GRVHDQGDWD QGKRXUVSRVWGRVH VDPSOHV
SHUGRVH
3ULPDU\SKDUPDFRNLQHWLFPHDVXUHVLQFOXGH7 PD[&PD[$8&WDQG$8& LQI6HFRQGDU\
SKDUPDFRNLQHWLFPHDVXUHVLQFOXGHWKHUDWLRRI$8& WWR$8& LQI7.HO&O)DQG9G)
6WDWLVWLFDOVXPPDULHVIRUDJLYHQSHULRGZLOOLQFOXGHGDWDIURPDOOVXEM HFWVIRUZKRPLWZDVD
FRPSOHWHGSHULRGHYHQWKR VHZKRGRQRWFRPSOHWHDOOIRXUSHULRGV7KHSULPDU\PL[HG PRGHODQDO\VHV
IRUUHODWLYHELRDYDLODELOLW\GRVHDQGIRRG ZLOOXVHDOOWKHGDWDIURPDOOFRPSOHWHGSHULRGV
'HVFULSWLYHVWDWLVWLFVZLOOEHXVHGWR VXPPDUL]H SUHWRPDQLGSODVPDFRQFHQWUDWLRQVDWHDFKVDPSOLQJ
WLPHSRLQWDQG IRUGHULYHGSODVPD3.SDUDPHWHUVDVDSSOLFDEOH6WDWLVWLFVLQ FOXGHVDPSOHVL]HQ
PHDQ6'SHUFHQWDJHFRHIILFLHQWRIYDULDWLRQ&9JHRPHWULFPHD QPHGLDQPLQLPXPDQG
PD[LPXP
$OOGDWDZLOOEHOLVWHGHYHQLIQRWXVHGIRUVWDWLVWLFDOVXPPDULHV RUPRGHOEDVHGDQDO\VHV%XWGDWDWKDW
GRQRWFRPHIURPFRPSOHW HGSHULRGVZLOOEHFKDUDFWHUL]HGLQWKHOLVWLQJDVWRWKHLUGHI LFLHQF\
)RUHDFKSDUWLFLSDQWSUHWRPDQLGSODVPDFRQFHQWUDWLRQ WLPHGDWDZLOOEHJUDSKLFDOO\SUHVHQWHG
6LPLODUO\JUDSKVRIWKHPHDQSODVPDFRQFHQWUDWLRQWLPHSURILOH VDQGRYHUOD\JUDSKVZLWKFRPELQHGGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 6
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHYLQGLYLGXDOSODVPDFRQFHQWUDWLRQWLPHSURILOHVZLOOEHSURGXFHG $GGLWLRQDOO\SKDUPDFRNLQHWLF
SDUDPHWHUVPD\EHH[SORUHG JUDSKLFDOO\
7KHELRDYDLODELOLW\RI[ PJGLVSHUVLEOHWDEOHWVUHODWLYHWRWKHPJUHIHUHQFHWDEOHW ZLOOEH
GHWHUPLQHGVHS DUDWHO\IRUHDFKSDQHOXVLQJDPL[HGPRGHOZLWKWKHORJWUDQVIR UPHG3.SDUDPHWHU
&PD[$8&WDQG$8& LQIDVUHVSRQVHYDULDEOHVHTXHQF HSHULRGDQGWUHDWPHQWDVIL[HGHIIHFWVDQG
SDUWLFLSDQWDVUDQGR PHIIHFW
7KHHIIHFWRIGRVHRQWKHUHODWLYHELRDYDLODELOLW\RIWKHGLVSHUVLE OHWDEOHWZLOOEHGHWHUPLQHGVHSDUDW HO\
IRUHDFKSDQHOXVLQJWKHVDPHPRGHODVDERYH 
7KHHIIHFWR IIRRGRQWKHUHODWLYHELRDYDLODELOLW\RISUHWRPDQLGZLOOEHGH WHUPLQHGFRPSDUL QJDFURVV
SDQHOVHDFKIRUPXODWLRQDQGGRVHWDNHQDIWHUHDWLQJEUHDNIDVWYH UVXVWKHVDPHIRUPXODWLRQDQGGRVH
WDNHQLQIDVWHGFRQGLWLRQVXVLQJDPL[HGPRGHOZLWKWKHORJWUDQVI RUPHG3.SDU DPHWHUDVUHVSRQVH
YDULDEOHSDQHOVHTXHQFHSHULRGWUHDWPHQWDQ GSDQHOE\WUHDWPHQWLQWHUDFWLRQDVIL[HGHIIHFWV DQG
SDUWLFLSDQWDVUDQGR PHIIHFW
7KH7PD[RISUHWRPDQLGIRUHDFKRIWKHIRUPXODWLRQVZLOOEHGHVFULSWLYHO \FRPSDUHG
2WKHUVWDWLVWLFDOPRGHOVDQGRUSRSXODWLRQSKDUPDFRNLQHWLFPRGHOOLQJ PD\DOVREHXVHG IRUIXUWKHUGDWD
LQWHUSUHWDWLRQ 
6DIHW\
7KH,QYHVWLJDWRUZLOOHYDOXDWHVDIHW\XVLQJWKHIROORZLQJDVVHVVPHQWV SK\VLFDOH[DPLQDWLRQVYLWDOVLJQ
PHDVXUHPHQWVFOLQLFDOODERUDW RU\HYDOXDWL RQVHOHFWURFDUGLRJUDPV(&*VDQGUHSRUWHGRUREVHUYHG
DGYHUVHHY HQWV$(V6XEMHFWVZLOOEHPRQLWRUHGFRQWLQXRXVO\IRUDQ\$(V IURPWKHVLJ QLQJRIWKH
LQIRUPHGFRQVH QWWKURXJKWKHHQGRIWKHVWXG\,QDGGLWLRQYLWDOVLJQVZLOO EHLQYHVWLJD WHGSULRUWRHDFK
GRVHDQGGDLO\ DVZHOODVGD\VDIWHUWKHODVW3.VDPSOH(&*VZLOOEHREWDL QHGSULRUWRHDFK GRVHDQG
GD\VDIWHUWKHODVW3.VDPSOH&OLQLFDOODERUD WRU\WHVWVZLOOEHLQYHVWLJDWHGSULRUWRHDFKGRVHDQG
KRXUVSRVWGRVLQJDVZHOODVGD\VDIWHUWKHODVW3.VDPSOH 6DIHW\IROORZXSLVSO DQQHGGD\V
IROORZLQJWKHODVW3.VD PSOHLQWKHODVWWUHDWPHQWVHVVLRQRUDIWHUGURSRXW
(IILFDF\1RHIILFDF\HYDOXDWLRQVZLOOEHSHUIRUPHGLQWKLVVWXG\
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 7
3URWRFRO3D&/9
7%$OOLDQFH 'HF &21),'(17,$/
3DJHYL7$%/(2)&217(176
35272&2/$33529$/3$*( LL  
35272&2/6<1236,6  LLL 
7$%/(2)&217(176  YL 
/,672)7$%/(6  YLL  
/,672)$%%5(9,$7,216 YLL L 
 ,1752'8&7,21   
 &OLQLFDO6WXGLHV   
 3KDUPDFRNLQHWLFV   
 6WXG\5DWLRQDOH    
 2%-(&7,9(6   
 678'<'(6,*16800$5<   
 68%-(&76(/(&7,21   
 ,QFOXVLRQ&ULWHULD    
 ([FOXVLRQ&ULWHULD   
 $FWLYLW\5HVWULFWLRQV   
 &RQWUDFHSWLRQ5HTXLUHPHQWV   
 6FUHHQLQJ    
 678'<352&('85(6   
 6XEMHFW$VVLJQPHQW   
 &KHFN,Q3URFHGXUHV   
 &RQILQHPHQW    
 )DVWLQJ0HDOV%HYHUDJHV   
  )DVWLQJ0HDOV    
  %HYHUDJHV    
 'UXJ$GPLQLVWUDWLRQ   
 %ORRG6DPSOLQJ3URFHVVLQJDQG6KLSPHQW   
 (QGRI6WXG\3URFHGXUHV   
 6DIHW\0RQLWRULQJDQG3URFHGXUHV   
  6DIHW\±$GYHUVH(YHQWV   
  6DIHW\±&OLQLFDO/DERUDWRU\(YDOXDWLRQV   
  6DIHW\±9LWDO6LJQV   
  6DIHW\±3K\VLFDO([DPLQDWLRQV   
  6DIHW\±(OHFWURFDUGLRJUDPV   
  2WKHU6DIHW\0HDVXUHV   
 $'9(56((9(176   
 'HILQLWLRQV    
  $GYHUVH(YHQW    
  6HULRXV$GYHUVH(YHQW   
 $WWULEXWLRQ&DXVDOLW\   Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 8
3URWRFRO3D&/9
7%$OOLDQFH 'HF &21),'(17,$/
3DJHYLL 5HSRUWLQJ    
  $GYHUVH(YHQW    
 6HULRXV$GYHUVH(YHQW5HSRUWLQJ   
 )ROORZXSRI$GYHUVH(YHQWV   
 3RVW7ULDO6HULRXV$GYHUVH(YHQWV   
 &OLQLFDO/DERUDWRU\$GYHUVH(YHQWV   
 'UXJ,QWHUDFWLRQ    
 3UHJQDQF\    
 *(1(5$/&216,'(5$7,216   
 %DVLF3ULQFLSOHV    
 ,QVWLWXWLRQDO5HYLHZ%RDUG   
 ,QIRUPHG&RQVHQW   
 ,QGLFDWLRQVIRU6XEMHFW:LWKGUDZDO   
 7HUPLQDWLRQRIWKH6WXG\   
 'RFXPHQWDWLRQ   
 7ULDO0RQLWRULQJ    
 5HLPEXUVHPHQW,QGHPQLW\DQG,QVXUDQFH   
 3+$50$&2.,1(7,&$1$/<6,6   
 $QDO\WLFDO0HWKRGRORJ\   
 3KDUPDFRNLQHWLFDQG6WDWLVWLFDO$QDO\VHV   
 )$&,/,7,(6   
 '58*6833/,(6   
 $'0,1,675$7,9(,668(6   
 (9(1766&+('8/(   
 5()(5(1&(6   
$33(1',;  3+$50$&2.,1(7,&6$03/(&2//(&7,21352&(66,1*$1'
6+,30(17,16758&7,216   
$33(1',;',9,6,212)0,&52%,2/2*<$1',1)(&7,286',6($6(72;, &,7<
7$%/(    
/,672)7$%/(6
7DEOH  ,GHQWLW\RI,QYHVWLJDWLRQDO3URGXFWV   
7DEOH  $FFHSWDEOH3KDUPDFRNLQHWLF6DPSOLQJ7LPH:LQGRZV   
7DEOH  $GYHUVH(YHQW$WWULEXWLRQ&DXVDOLW\5DWLQJV   
7DEOH  'HILQLWLRQVIRU$GYHUVH(YHQW6HYHULW\*UDGLQJV   
7DEOH  6FKHGXOHRI$VVHVVPHQWVDQG3URFHGXUHV   Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 9
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHYLLL/,672)$%%5(9,$7,216
$'/ DFWLYLW\RIGDLO\OLYLQJ
$( DGYHUVHHYHQW
$/3 DONDOLQHSKRVSKDWDVH
$/7 DODQLQHWUDQVDPLQDVH
$129$ DQDO\VLVRIYDULDQFH
$67 DVSDUWDWHWUDQVDPLQDVH
$8& DUHDXQGHUWKHSODVPDFRQFHQWUDWLRQYVWLPHFXUYH
$8&ODVW DUHDXQGHUWKHFXUYHIURPWLPHKRXUVWRODVWTXDQWLILDEOHFRQ FHQWUDWLRQ
$8&LQI DUHDXQGHUWKHFXUYHIURPWLPHKRXUVWRLQILQLW\
%0, ERG\PDVVLQGH[
%3 EORRGSUHVVXUH
%81 EORRGXUHDQLWURJHQ
ESP EHDWVSHUPLQXWH
&D FDOFLXP
&)5 &RGHRI)HGHUDO5HJXODWLRQV
&, FRQILGHQFHLQWHUYDO
&O FKORULGH
&ODVW ODVWTXDQWLILDEOHGUXJFRQFHQWUDWLRQ
&O) DSSDUHQWFOHDUDQFH
&/,$ &OLQLFDO/DERUDWRU\,PSURYHPHQW$PHQGPHQWV
FP FHQWLPHWHUV
&PD[ PD[LPXPFRQFHQWUDWLRQ
&16 FHQWUDOQHUYRXVV\VWHP
&5) FDVHUHSRUWIRUP
&7&$( &RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV
&<3 F\WRFKURPH3
'($ 'UXJ(QIRUFHPHQW$GPLQLVWUDWLRQ
G/ GHFLOLWHU
(&* HOHFWURFDUGLRJUDP
('7$ HWK\OHQHGLDPLQHWHWUDDFHWLFDFLG
(5 H[WHQGHGUHOHDVH
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ
IO IOXLG
)6+ IROOLFOHVWLPXODWLQJKRUPRQH
J JUDPV
*&3 *RRG&OLQLFDO3UDFWLFH
+,3$$ +HDOWK,QVXUDQFH3RUWDELOLW\DQG$FFRXQWDELOLW\$FW
+,9 KXPDQLPPXQRGHILFLHQF\YLUXV
+&O K\GURFKORULGHGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 10
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHL[,&' LQIRUPHGFRQVHQWGRFXPHQW
,&+,QWHUQDWLRQDO&RXQFLOIRU+DUPRQLVDWLRQRI7HFKQLFDO5HTXLUHPHQ WVIRU
3KDUPDFHXWLFDOVIRU+XPDQ8VH
,1' ,QYHVWLJDWLRQDO1HZ'UXJ
,3 ,QYHVWLJDWLRQDO3URGXFW
,5 LPPHGLDWHUHOHDVH
,5% LQVWLWXWLRQDOUHYLHZERDUG
,6) ,QYHVWLJDWRU6LWH)LOH
,8' LQWUDXWHULQHGHYLFH
. SRWDVVLXP
.HO WKHHOLPLQDWLRQUDWHFRQVWDQW
NJ NLORJUDPV
/ OLWHUV
OEV SRXQGV
/'+ ODFWDWHGHK\GURJHQDVH
/24 OLPLWRITXDQWLWDWLRQ
P PHWHUV
0$2, PRQRDPLQHR[LGDVHLQKLELWRU
PD[ PD[LPXP
PJ PLOOLJUDPV
PLQ PLQXWHV
P,8 PLOOLLQWHUQDWLRQDOXQLWV
P/ PLOOLOLWHUV
PP+J PLOOLPHWHURIPHUFXU\
PVHF PLOOLVHFRQG
QRU1 QXPEHURIRFFXUUHQFHV
1D VRGLXP
QJ QDQRJUDPV
27& 2YHUWKHFRXQWHU
R] RXQFHV
5%& UHGEORRGFHOO
5/' UHIHUHQFHOLVWHGGUXJ
USP UHYROXWLRQVSHUPLQXWH
6$( VHULRXVDGYHUVHHYHQW
6$3 VWDWLVWLFDODQDO\VLVSODQ
623 VWDQGDUGRSHUDWLQJSURFHGXUH
7òRUWòWHUPLQDOHOLPLQDWLRQKDOIOLIH
7ODJ WLPHSULRUWRWKHILUVWPHDVXUDEOHQRQ]HURFRQFHQWUDWLRQ
7ODVW WLPHRIWKHODVWPHDVXUDEOHFRQFHQWUDWLRQ
7PD[ WLPHWRUHDFK& PD[
9G) DSSDUHQWYROXPHRIGLVWULEXWLRQGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 11
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJH[8'6 XULQHGUXJVFUHHQ
:%& ZKLWHEORRGFHOOV
:&7 :RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV%LRDQDO\WLFDO6FL HQFHV//&
ȕK&* EHWDKXPDQFKRULRQLFJRQDGRWURSLQ
Ȝ]RU
/DPEGD]DSSDUHQWHOLPLQDWLRQUDWHFRQVWDQWLQWHUPLQDOSKDVH 
& GHJUHHV&HOVLXV&HQWLJUDGH

Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 12
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJH ,1752'8&7,21
7%$OOLDQFHKDVGHYHORSHGWZRLQYHVWLJDWLRQDOIRUPXODWLRQVDQG PJ
GLVSHUVLEOHWDEOHWVRISUHWRPDQLG3$WKDWDUHLQWHQGHGIRUSH GLDWULFXVH,QWKH
SUHVHQWVWXG\WKHSKDUPDFRNLQHWLFV3.DQGVDIHW\RIWKHGLVS HUVLEOHIRUPXODWLRQVZLOO
EHFRPSDUHGWRWKHDSSURYHGUHIHUHQFHSUHWRPDQLG3$PJW DEOHW7KLVWULDO
ZLOOEHFRQGXFWHGLQFRPSOLDQFHZLWKWKHSURWRFRO*RRG&OLQLFD O3UDFWLFH*&3DQG
DOODSSOLFDEOHUHJXODWRU\UHTXLUHPHQWV
3UHWRPDQLGLVLQGLFDWHGLQFRPELQDWLRQZLWKEHGDTXLOLQHDQGOLQH ]ROLGIRUWKHWUHDWPHQW
RIH[WHQVLYHO\UHVLVWDQWSXOPRQDU\WXEHUFXORVLV;'57%DQGRIP XOWLGUXJUHVLVWDQW
SXOPRQDU\0'57%WKDWLVQRQUHVSRQVLYHWRWUHDWPHQWRUZLWK GHPRQVWUDWHG
WUHDWPHQWLQWROHUDQFH7KHSXUSRVHRIWKHSUHVHQWVWXG\LVWRLQ YHVWLJDWHSUHWRPDQLG
IRUPXODWLRQVWKDWFRXOGEHXVHGIRUWKHWUHDWPHQWRI;'57%DQGQ RQUHVSRQVLYHRU
WUHDWPHQWLQWROHUDQW0'57%LQFKLOGUHQDVSDUWRIDFRPELQDWLR QUHJLPHQWKDWZLOO
DOVRLQFOXGHEHGDTXLOLQHDQGOLQH]ROLG7KHVDIHW\DQGSKDUPDFRNL QHWLFLQIRUPDWLRQ
EHORZLVH[FHUSWHGIURPWKH,QYHVWLJDWRU¶V%URFKXUH,%IRU3UH WRPDQLG3$
 &OLQLFDO 6WXGLHV
7KHFOLQLFDOSURJUDPRISUHWRPDQLGKDVLQFOXGHG3KDVHVWXGLHV LQKHDOWK\YROXQWHHUV
WRHYDOXDWHWKHVDIHW\WROHUDELOLW\DQG3.RIWKLVQRYHODJHQ WLQKXPDQVDVZHOODV
3KDVHWULDOVWRH[SORUHLWVP\FREDFWHULFLGDODFWLYLW\GRVHU HVSRQVH3.DQGVDIHW\LQ
VXEMHFWVZLWKQHZO\GLDJQRVHGSXOPRQDU\7%$WWKHWLPHRIWKH ,%GDWDFXWRIIGDWD
0D\SUHWRPDQLGHLWKHUDORQHRUDVSDUWRIDFRPELQD WLRQUHJLPHQKDVEHHQ
XVHGLQDWOHDVWFOLQLFDOWULDOVVSRQVRUHGE\HLWKHU7%$OOL DQFHRUDQRWKHUHQWLW\LQ
PRUHWKDQVXEMHFWV7ZHQW\RQHRIWKHWULDOVDUHFRQVLGHU HGDVWKHFRUHRIWKH
SUHWRPDQLGGHYHORSPHQWDOSURJUDP6DIHW\GDWDIRUSUHWRPDQLGVX PPDUL]HGEHORZDUH
EDVHGRQVXEMHFWVIURPWULDOVLQFOXGLQJVXEMHFWV ZLWKHLWKHU;'57%RU
0'57%VXEMHFWVZLWKGUXJVXVFHSWLEOH'67%DQGKHD OWK\YROXQWHHUV
,QWKHVHWULDOVSUHWRPDQLGZDVHLWKHUDGPLQLVWHUHGDORQHRUDV SDUWRIDFRPELQDWLRQ
UHJLPHQVHH $SSHQGL[ LQWKH,%$GYHUVHHYHQWV$(VZHUHLGHQWLILHGIURPWKH
SRROHGVDIHW\GDWDEDVHEDVHGXSRQDV\VWHPDWLFDQGZHOOGRFXPHQ WHGDSSURDFK7KH
SURILOHIRUFRPPRQ$(VYDULHGDFURVVWKHSRROLQJJURXSVPRVWO LNHO\GXHWRYDULDWLRQV
LQVXEMHFWSRSXODWLRQWKHW\SHVRIGUXJVXVHGLQWKHWUHDWPHQW UHJLPHQVDQGWKH
GXUDWLRQRIH[SRVXUH,QWKH3KDVHSRROLQZKLFKVXEMHFW VZHUHH[SRVHGWRD
VLQJOHGRVHRISUHWRPDQLGUDQJLQJIURPWRPJDQGV XEMHFWVZHUHH[SRVHG
WRUHSHDWHGGDLO\GRVHVRISUHWRPDQLGUDQJLQJIURPPJWR PJIRUXSWR
GD\VDWOHDVW$(ZDVUHSRUWHGLQRISUHWRPDQLGWUHDWHG VXEMHFWVWKHDOO
SUHWRPDQLGJURXSDQGLQRIFRQWUROVXEMHFWV7KHLQFLGHQ FHRIDQ\$(ZDV
ORZHULQWKHVLQJOHGRVHSUHWRPDQLGPJJURXSWKDQLQWKHR WKHUSUHWRPDQLG
JURXSVYHUVXVDUDQJHRIWR7KHPRVWIUHTX HQWO\RIGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 13
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHVXEMHFWVUHSRUWHG$(VLQWKHDOOSUHWRPDQLGJURXSZHUHKHDGDFKH QDXVHD
GHFUHDVHGKHPRJORELQDQGFRQWDFWGHUPDWLWLV 7KHRQO\$(
LQWKHFRQWUROJURXSUHSRUWHGLQDWOHDVWRIVXEMHFWVZDVK HDGDFKHZLWKDQ
LQFLGHQFHORZHUWKDQWKDWLQWKHDOOSUHWRPDQLGJURXSYH UVXV+HDGDFKH
ZDVPRUHFRPPRQLQWKHPXOWLSOHGRVHSUHWRPDQLG!PJJURXSW KDQLQWKHRWKHU
SUHWRPDQLGJURXSVYHUVXVDUDQJHRIWR1DX VHDRFFXUUHGPRUH
IUHTXHQWO\LQWKHVLQJOHDQGPXOWLSOHGRVHSUHWRPDQLG!PJJU RXSVDQG
UHVSHFWLYHO\WKDQLQWKHVLQJOHGRVHSUHWRPDQLGPJ DQGPXOWLSOHGRVH
PJJURXSVDQGUHVSHFWLYHO\'HFUHDVHGKHPRJOREL QDQGFRQWDFW
GHUPDWLWLVZHUHREVHUYHGSULPDULO\LQWKHVLQJOHGRVHSUHWRPDQLG !PJJURXS
YHUVXVIRURWKHUSUHWRPDQLGJURXSVIRUKHPRJORELQGHFUH DVHG
YHUVXVDUDQJHRIWRIRUGHUPDWLWLVFRQWDFW7KHGHFUHDV HLQKHPRJORELQ
RFFXUUHGSULPDULO\LQWKHWKRURXJK47VWXG\ZKLFKLQYROYHGPXOW LSOHEORRGGUDZVDQG
(&*SDGDSSOLFDWLRQV
7UHDWPHQWUHODWHG$(VLGHQWLILHGIURPWKHSRROHGVDIHW\GDWDEDVH RIUHSRUWHG$(VLQ
WKH3KDVHVWXGLHVZKHUHSODFHERDUPZDVDYDLODEOHDQG3KDVH DQGFOLQLFDOVWXGLHV
ZKHUHDVWDQGDUGRIFDUHDUPZDVDYDLODEOHLQFOXGHGQDXVHDYRPLW LQJUDVKDQG
LQFUHDVHGWUDQVDPLQDVHV,QFUHDVHGWUDQVDPLQDVHVZHUHQRWVHHQLQ 3KDVHVWXGLHVEXW
ZHUHUHSRUWHGLQVWXGLHVWKDWHQUROOHGSDWLHQWVZLWK0'57%RU ;'57%ZKRKDG
PXOWLSOHFRPRUELGLWLHVDQGUHFHLYHGSUHWRPDQLGLQFRPELQDWLRQZLW KRWKHUDQWL
WXEHUFXORVLVGUXJV
 3KDUPDFRNLQHWLFV
,PSRUWDQWGULYHUVRI3.YDULDELOLW\DUHGRVLQJZLWKRUZLWKRXWI RRGDQG
FRDGPLQLVWUDWLRQRIPHGLFDWLRQVWKDWLQGXFH&<3$
%LRDYDLODELOLW\LQWKHIDVWHGVWDWHZDVDERXWKDOIWKDWLQWKH IHGVWDWHZKHQSUHWRPDQLG
ZDVDGPLQLVWHUHGDWWKHFOLQLFDOGRVHRIPJ
,QWKHSUHVHQFHRIULIDPSLFLQDQGHIDYLUHQ]SUHWRPDQLGDUHDXQG HUWKHFXUYH$8&
ZDVUHGXFHGDQGUHVSHFWLYHO\6XFKVWURQJDQGPRGHUDWH &<3$LQGXFHUV
VKRXOGEHDYRLGHGZLWKSUHWRPDQLG1RFOLQLFDOO\VLJQLILFDQWGLI IHUHQFHVLQWKH
SKDUPDFRNLQHWLFVRISUHWRPDQLGZHUHREVHUYHGEDVHGRQVH[ERG\ ZHLJKWUDFHEODFN
&DXFDVLDQRURWKHUSXOPRQDU\7%VWDWXVRUKXPDQLPPXQRGHILFL HQF\VWDWXV+,9
VWDWXV7KHHIIHFWRIUHQDORUKHSDWLFLPSDLUPHQWRQWKHSKDUPDF RNLQHWLFVRISUHWRPDQLG
LVSUHVHQWO\XQNQRZQEXWLVEHLQJLQYHVWLJDWHGLQWZRRQJRLQJVWXG LHV
 6WXG\5DWLRQDOH
0'5DQG;'57%KDYHEHFRPHPRUHDQGPRUHZLGHVSUHDG7UHDWPHQWUH TXLUHV
FRPSOH[SURORQJHGUHJLPHQVZLWKVLJQLILFDQWWR[LFLW\DQGUHODWLY HO\ORZFXUHUDWHV,Q
$XJXVW)'$DSSURYHGWKHXVHRISUHWRPDQLGLQFRPELQDWLRQZL WKEHGDTXLOLQH
DQGOLQH]ROLG%3D/UHJLPHQIRUWKHWUHDWPHQWRI;'57%DQGVH OHFWHGIRUPVRIGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 14
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH0'57%7KLVDOORUDOPRQWKWUHDWPHQWUHJLPHQZDVDVVRFLDWH GZLWKFXUHUDWHVRI
DSSUR[LPDWHO\DQGPDQDJHDEOHWR[LFLW\0'5DQG ;'575%DUHOHVVFRPPRQ
LQFKLOGUHQLWLVH[SHFWHGWKDWWKHLULQFLGHQFHLQWKLVSRSXOD WLRQZLOOLQFUHDVHGXHWR
LQFUHDVLQJWUDQVPLVVLRQRIGUXJUHVLVWDQW07EVWUDLQV7KHUHIRU HWKHUHLVDQLPSRUWDQW
XQPHWPHGLFDOQHHGWRLQYHVWLJDWHWUHDWPHQWRSWLRQVIRUGUXJUH VLVWDQWIRUPVRI7%LQ
SHGLDWULFSDWLHQWV2XUIXWXUHJRDOLVWRLQYHVWLJDWHWKH%3D/ UHJLPHQLQFKLOGUHQZLWK
0'5DQG;'57%7KHSUHVHQWWULDOLVGHVLJQHGWRLQYHVWLJDWH SUHWRPDQLG
IRUPXODWLRQVLQWHQGHGIRUSHGLDWULFXVH
3UHWRPDQLGLVSURYLGHGIRUDGXOWVDVDQLPPHGLDWHUHOHDVHWDEOH WZLWKPJDFWLYH
VXEVWDQFH7KHVDPHSURGXFWLVIRUHVHHQIRUDGROHVFHQWV\HDU VDQGROGHU)RU
SDWLHQWV\RXQJHUWKDQ\HDUVGLVSHUVLEOHVFRUHGWDEOHWVFRQW DLQLQJDQGPJ
SUHWRPDQLGDUHFXUUHQWO\EHLQJGHYHORSHGZKLFKZRXOGEHXVHGW RDGMXVWGRVHVEDVHG
RQERG\ZHLJKW
$QH[WUDSRODWLRQDSSURDFKLVLQWHQGHGIRUWKHSHGLDWULFFOLQLFD OGHYHORSPHQWSURJUDP
7KLVZLOOEHEDVHGRQWKHLGHQWLILFDWLRQRIGRVHVLQFKLOGUHQ\ LHOGLQJH[SRVXUHWR
SUHWRPDQLGWKDWFRUUHVSRQGVWRWKHH[SRVXUHLQDGXOWSDWLHQWVZ KHUHHIILFDF\KDVEHHQ
GHPRQVWUDWHG
7KLVVWXG\ZLOOHYDOXDWHWKHUHODWLYHELRDYDLODELOLW\RIWKHGL VSHUVLEOHWDEOHWFRPSDUHGWR
WKDWRIWKHLPPHGLDWHUHOHDVHWDEOHWXVHGIRUGRVLQJRIDGROHVF HQWVDQGDGXOWV,Q
DGGLWLRQDSRWHQWLDOIRRGHIIHFWZLOOEHHYDOXDWHG7KLVVWXG\ ZLOOEHFRQGXFWHGLQ
KHDOWK\DGXOWYROXQWHHUV
2%-(&7,9(6
3ULPDU\2EMHFWLYH
x7RDVVHVVWKHUHODWLYHELRDYDLODELOLW\RIWKHVLQJOHGRVHGLVSH UVLEOHIRUPXODWLRQ
LQWHQGHGIRUSHGLDWULFWUHDWPHQWXVLQJWKHPJVLQJOHGRVH LPPHGLDWHUHOHDVH
IRUPXODWLRQDVWKHUHIHUHQFH
6HFRQGDU\2EMHFWLYHV
x7RGHWHUPLQHWKHIRRGHIIHFWIRUHDFKRIWKHIRUPXODWLRQV
x7RDVVHVVWKHHIIHFWRIGRVHRQWKHELRDYDLODELOLW\RIWKHGLVS HUVLEOHSHGLDWULF
IRUPXODWLRQXQGHUIHGDQGIDVWHGFRQGLWLRQV
x7RHYDOXDWHWKHWDVWHSHUFHSWLRQRIWKHGLVSHUVLEOHSHGLDWULFI RUPXODWLRQXQGHUIHG
DQGIDVWHGFRQGLWLRQV
x7RHYDOXDWHWKHVKRUWWHUPVDIHW\DQGWROHUDELOLW\IRUHDFKRI WKHIRUPXODWLRQV
XQGHUIHGDQGIDVWHGFRQGLWLRQVGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 15
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJH 678'<'(6,*16800$5<
(DFKSDQHORIVXEMHFWVZLOOEHUDQGRPL]HGDFFRUGLQJWRWKHVDP HVHTXHQFH
SHULRG:LOOLDPVGHVLJQLQZKLFKHDFKSDUWLFLSDQWZLOOUHFHLY HIRXUVLQJOHGRVH
WUHDWPHQWV6XEMHFWVLQ3DQHOZLOOUHFHLYHDOOWUHDWPHQWVDIWH UFRQVXPLQJDQ)'$
VWDQGDUGKLJKIDWKLJKFDORULHEUHDNIDVWIROORZLQJDQRYHUQLJK WIDVWRIDWOHDVW
KRXUV6XEMHFWVLQ3DQHOZLOOUHFHLYHDOOWUHDWPHQWVGLUHFWO\ IROORZLQJDQRYHUQLJKW
IDVWRIDWOHDVWKRXUV7KHWZRSDQHOVZLOOEHLQYHVWLJDWHGF RQFXUUHQWO\ )LJXUH
VKRZVWKHWULDOVFKHPDWLF
)LJXUH 7ULDO6FKHPDWLF
6HVVLRQ,
'D\V 'D\V6HVVLRQ,,
'D\V 'D\V
3DQHO
7UHDWPHQW$%&RU'VLQJOH GRVHZLWK
EUHDNIDVW
RU
3DQHO
7UHDWPHQW$%&RU'DIWHUD KRXURYHUQLJKW
IDVWGD\EUHDN 3DQHO
7UHDWPHQW$%& RU'
VLQJOHGRVHZLWKEUHDNIDVW
RU
3DQHO
7UHDWPHQW$%&RU'DIWHUD
KRXURYHUQLJKW IDVWGD\EUHDN
6HVVLRQ,,,
'D\V'D\V6HVVLRQ,9
'D\V)ROORZXS9LVLW
'D\
3DQHO
7UHDWPHQW$%&RU'VLQJOHGRVHZLWK
EUHDNIDVW
RU
3DQHO
7UHDWPHQW $%&RU'DIWHUD KRXURYHUQLJKW
IDVWGD\EUHDN 3DQHO
7UHDWPHQW$%&RU'
VLQJOHGRVHZLWKEUHDNIDVW
RU
3DQHO
7UHDWPHQW$%&RU'DIWHUD
KRXURYHUQLJKWIDVWGD\VDIWHUODVW
3.VDPSOHLQ
6HVVLRQ,9
7KHVFUHHQLQJSHULRGZLOOEHJLQZLWKLQGD\VRIWKHILUVWSDUWLFL SDQWEHLQJGRVHG
6XEMHFWVZLOOEHDVVLJQHGQXPEHUVLQDQDVFHQGLQJRUGHUEDVHG RQVXFFHVVIXO
FRPSOHWLRQRIWKHVFUHHQLQJSURFHVV
6XEMHFWVZLOOUHFHLYHDVLQJOHGRVHRIHDFKWUHDWPHQWOLVWHGLQ 7DEOHLQUDQGRPL]HG
IDVKLRQGXULQJWKHIRXUWUHDWPHQWSHULRGVGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 16
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJH7DEOH ,GHQWLW\RI,QYHVWLJDWLRQDO3URGXFWV
5HIHUHQFH3URGXFW7UHDWPHQW$ 3UHWRPDQLG3$
Dose = [PJWDEOHWXVLQJWKHLPPHGLDWHUHOHDVHIRUPXODWLRQ
RUDOO\DGPLQLVWHUHG
7%$OOLDQFH
7HVW3URGXFW7UHDWPH
QW%3UHWRPDQLG3$
'RVH [PJGLVSHUVLEOHWDEOHWVPJWRWDORUDOO\DGPLQLVWHUHGDVGLVSHUVLRQLQZDWHU
7%$OOLDQFH
7HVW3URGXFW
7UHDWPHQW&3UHWRPDQLG3$
'RVH [PJGLVSHUVLEOHWDEOHWRUDOO\DGPLQLVWHUHGDVGLV SHUVLRQ
LQZDWHU
7%$OOLDQFH
7HVW3URGXFW7
UHDWPHQW'3UHWRPDQLG3$
'RVH [PJGLVSHUVLEOHWDEOHWRUDOO\DGPLQLVWHUHGDVGLV SHUVLRQ
LQZDWHU
7%$OOLDQFH
(DFKVWXG\WUHDWPHQWDGPLQLVWUDWLRQZLOOEHVHSDUDWHGE\DZDVKR XWSHULRGRIGD\V
$QRXWSDWLHQWVDIHW\IROORZXSYLVLWLVSODQQHGDSSUR[LPDWHO\GD\V IROORZLQJWKHODVW
SKDUPDFRNLQHWLFVDPSOHLQWKHODVWWUHDWPHQWSHULRGRUDIWHUGUR SRXW
'XULQJHDFKVWXG\SHULRGP/EORRGVDPSOHVZLOOEHREWDLQHGE HIRUHVWXG\GUXJ
DGPLQLVWUDWLRQDQGDWVHOHFWHGWLPHVWKURXJKKRXUVDIWHUVWXG\ GUXJDGPLQLVWUDWLRQ
$WRWDORISKDUPDFRNLQHWLFEORRGVDPSOHVZLOOEHFROOHFWHGIU RPHDFKVXEMHFW
VDPSOHVLQHDFKVWXG\SHULRG3ODVPDSKDUPDFRNLQHWLFVDPSOHVZ LOOEHDQDO\]HGIRU
SUHWRPDQLGXVLQJDYDOLGDWHGDQDO\WLFDOPHWKRG$SSURSULDWHSKD UPDFRNLQHWLF
SDUDPHWHUVZLOOEHFDOFXODWHGIRUHDFKIRUPXODWLRQXVLQJQRQFR PSDUWPHQWDOPHWKRGV
)RRGDQGZDWHUFRQVXPSWLRQZLOOIROORZWKHJXLGHOLQHVLQ 6HFWLRQ 6XEMHFWVZKR
ZLWKGUDZIURPWKHVWXG\ZLOOQRWEHUHSODFHG
 68%-(&76(/(&7,21 ,QFOXVLRQ&ULWHULD
$OOYROXQWHHUVPXVWVDWLVI\WKHIROORZLQJFULWHULDWREHFRQVLGH UHGIRUVWXG\
SDUWLFLSDWLRQ
 9ROXQWDULO\FRQVHQWVWRSDUWLFLSDWHLQWKLVVWXG\DQGSURYLGHVZ ULWWHQLQIRUPHG
FRQVHQWEHIRUHWKHVWDUWRIDQ\VWXG\VSHFLILFSURFHGXUHV
 0DOHRUIHPDOH)HPDOHVPXVWQRWEHSUHJQDQWRUEUHDVWIHHGLQJ 
 :LOOLQJDQGDEOHWRFRPSO\ZLWKWKHFRQWUDFHSWLRQUHTXLUHPHQW VVHH6HFWLRQ 
 %HWZHHQDQG\HDUVRIDJHLQFOXVLYHDWWKHWLPHRIVFUHHQ LQJGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 17
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH%RG\PDVVLQGH[%0,EHWZHHQDQGNJPLQFOXVLYHDQGZHLJKVD
PLQLPXPRINJ
:LOOLQJDQGDEOHWRUHPDLQLQWKHVWXG\XQLWIRUWKHHQWLUHFRQ ILQHPHQWSHULRGDQG
UHWXUQIRUWKHRXWSDWLHQWIROORZXSYLVLW
:LOOLQJDQGDEOHWRFRQVXPHWKHHQWLUHKLJKFDORULHKLJKIDWE UHDNIDVWPHDOLQWKH
WLPHIUDPHUHTXLUHGGXULQJWKHGHVLJQDWHGVWXG\SHULRG
:LOOLQJDQGDEOHWRFRPSO\ZLWKWKHSURWRFRODQGWKHDVVHVVPHQW VWKHUHLQ
LQFOXGLQJDOOUHVWULFWLRQV
([FOXVLRQ&ULWHULD
9ROXQWHHUVZLOOEHH[FOXGHGIURPVWXG\SDUWLFLSDWLRQIRUDQ\RI WKHIROORZLQJ
+LVWRU\RUSUHVHQFHRIFOLQLFDOO\VLJQLILFDQWFDUGLRYDVFXODUS XOPRQDU\KHSDWLF
UHQDOKHPDWRORJLFJDVWURLQWHVWLQDOHQGRFULQHLPPXQRORJLFG HUPDWRORJLF
QHXURORJLFRQFRORJLFRUSV\FKLDWULFGLVHDVHRUDQ\RWKHUFRQG LWLRQWKDWLQWKH
RSLQLRQRIWKH,QYHVWLJDWRUZRXOGMHRSDUGL]HWKHVDIHW\RIWKH VXEMHFWRUWKH
YDOLGLW\RIWKHVWXG\UHVXOWV
$FOLQLFDOO\VLJQLILFDQWDEQRUPDOILQGLQJRQWKHSK\VLFDOH[DPL QDWLRQPHGLFDO
KLVWRU\HOHFWURFDUGLRJUDP(&*RUFOLQLFDOODERUDWRU\UHVXOW V
9LWDOVLJQVDWVFUHHQLQJPHDVXUHGVLWWLQJDIWHUDPLQLPXPPL QXWHVUHVWDV
IROORZVEORRGSUHVVXUHLVOHVVWKDQPP+JRUJUHDWHUWKDQ PP+JRU
DKHDUWUDWHORZHUWKDQESPRUKLJKHUWKDQESP2XWRIUD QJHYLWDOVLJQV
PD\EHUHSHDWHGRQFH
+LVWRU\RUSUHVHQFHRIDOOHUJLFRUDGYHUVHUHVSRQVHWRSUHWRPDQ LGRUUHODWHGGUXJV
2QDVLJQLILFDQWO\DEQRUPDOGLHWGXULQJWKHZHHNVSUHFHGLQJW KHILUVWGRVHRI
VWXG\PHGLFDWLRQ
3DUWLFLSDWLRQLQDQRWKHUFOLQLFDOWULDOUDQGRPL]HGVXEMHFWVRQ O\ZLWKLQGD\V
EHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQ
8VHRIDQ\RYHUWKHFRXQWHU27&PHGLFDWLRQLQFOXGLQJQXWULWL RQDORUGLHWDU\
VXSSOHPHQWVKHUEDOSUHSDUDWLRQVRUYLWDPLQVZLWKLQGD\VEH IRUHWKHILUVWGRVH
RIVWXG\PHGLFDWLRQXQWLOWKHHQGRIVWXG\YLVLWZLWKRXWHYDOXD WLRQDQGDSSURYDO
E\WKH,QYHVWLJDWRU8SWRJUDPVSHUGD\RIDFHWDPLQRSKHQLV DOORZHGDWWKH
GLVFUHWLRQRIWKH,QYHVWLJDWRUSULRUWRGRVLQJ
8VHRIDQ\SUHVFULSWLRQPHGLFDWLRQH[FHSWKRUPRQDOFRQWUDFHSWL YHRUKRUPRQDO
UHSODFHPHQWWKHUDS\IURPGD\VEHIRUHWKHILUVWGRVHRIVWXG \PHGLFDWLRQXQWLO
WKHHQGRIVWXG\YLVLWZLWKRXWHYDOXDWLRQDQGDSSURYDOE\WKH, QYHVWLJDWRU
8VHRIDQ\GUXJVRUVXEVWDQFHVNQRZQWRORZHUWKHVHL]XUHWKUHV KROGGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 18
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH8VHRIDQ\GUXJVRUWUHDWPHQWZLWKDQ\NQRZQGUXJVWKDWDUHPRG HUDWHRUVWURQJ
LQGXFHUVRULQKLELWRUVRIF\WRFKURPH3&<3HQ]\PHVHJ EDUELWXUDWHV
SKHQRWKLD]LQHVFLPHWLGLQHFDUEDPD]HSLQHDQGRU3JSLQFOXGL QJ6W-RKQ¶V
:RUWZLWKLQGD\VEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQ DQGWKDWLQWKH
,QYHVWLJDWRU¶VMXGJPHQWPD\LPSDFWVXEMHFWVDIHW\RUWKHYDOLG LW\RIWKHVWXG\
UHVXOWV
)HPDOHZLWKDSRVLWLYHSUHJQDQF\WHVWUHVXOW
3RVLWLYHXULQHVFUHHQIRUGUXJVRIDEXVHDPSKHWDPLQHVEDUELWX UDWHV
EHQ]RGLD]HSLQHVFRFDLQHFDQQDELQRLGVRSLDWHVRUFRWLQLQH
3RVLWLYHWHVWIRUKHSDWLWLV%VX UIDFHDQWLJHQKHSDWLWLV&DQWL ERG\RUKXPDQ
LPPXQRGHILFLHQF\YLUXV+,9DWVFUHHQLQJRUKDVEHHQSUHYLRXVO \WUHDWHGIRU
KHSDWLWLV%KHSDWLWLV&RU+,9LQIHFWLRQ
+HPRJORELQJG/
$/7RU$67![WKHXSSHUOLPLWRIQRUPDO8/1
+\SHUELOLUXELQHPLD![8/1
6XUJHU\ZLWKLQWKHSDVWGD\VSULRUWRGRVLQJDVGHWHUPLQHGE \WKH,QYHVWLJDWRU
WREHFOLQLFDOO\UHOHYDQW
+LVWRU\RUSUHVHQFHRIDOFRKROLVPRUGUXJDEXVHZLWKLQWKHSDVW \HDUVDV
GHWHUPLQHGE\WKH,QYHVWLJDWRUWREHFOLQLFDOO\UHOHYDQW
$Q\FOLQLFDOO\VLJQLILFDQWHOHFWURFDUGLRJUDPDEQRUPDOLW\DW6FU HHQLQJDVGHHPHG
E\GHFLVLRQRIWKH,QYHVWLJDWRUDQGWKH6WXG\6SRQVRU¶V0HGLFDO 0RQLWRU
1RWH7KHIROORZLQJPD\EHFRQVLGHUHGQRWFOLQLFDOO\VLJQLILFDQ WZLWKRXW
FRQVXOWLQJWKH6SRQVRU¶V0HGLFDO0RQLWRU
D0LOGILUVWGHJUHH$9EORFN35LQWHUYDOVHF
E5LJKWRUOHIWD[LVGHYLDWLRQ
F,QFRPSOHWHULJKWEXQGOHEUDQFKEORFN
G,VRODWHGOHIWDQWHULRUIDVFLFXODUEORFNOHIWDQWHULRUKHPLEORF NLQ\RXQJHUDWKOHWLF
SDUWLFLSDQWV
47F)LQWHUYDO!PVHFIRUPDOHVRU!PVHFIRUIHPDOHVDWV FUHHQLQJ
'D\RU'D\SUHGRVHRUKLVWRU\RISURORQJHG47V\QGURP H
)DPLO\KLVWRU\RI/RQJ476\QGURPHRUVXGGHQGHDWKZLWKRXWDSU HFHGLQJ
GLDJQRVLVRIDFRQGLWLRQWKDWFRXOGEHFDXVDWLYHRIVXGGHQGHDW KVXFKDVNQRZQ
FRURQDU\DUWHU\GLVHDVHFRQJHVWLYHKHDUWIDLOXUHRUWHUPLQDOF DQFHUGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 19
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH$FWLYLW\5HVWULFWLRQV
6XEMHFWPXVWQRWGRQDWHEORRGIURPGD\VRUSODVPDIURPGD\ VSULRUWRWKH
ILUVWGRVHRIVWXG\PHGLFDWLRQXQWLODIWHUIROORZXSSKRQHFDOO ,WLVUHFRPPHQGHG
WKDWEORRGSODVPDGRQDWLRQVQRWEHPDGHIRUDWOHDVWGD\VDI WHUGLVFKDUJHIURP
WKHFOLQLF
6XEMHFWPXVWQRWXVHWREDFFRRUQLFRWLQHFRQWDLQLQJSURGXFWV LQFOXGLQJVPRNLQJ
FHVVDWLRQSURGXFWVIURPPRQWKVSULRUWRWKHILUVWGRVHRIVW XG\PHGLFDWLRQXQWLO
DIWHUWKHIROORZXSSKRQHFDOO
6XEMHFWPXVWQRWFRQVXPHDOFRKROIURPKRXUVSULRUWRWKHILU VWGRVHRIVWXG\
PHGLFDWLRQXQWLODIWHUGLVFKDUJHIURPWKHFOLQLF
6XEMHFWPXVWQRWFRQVXPHEHYHUDJHVRUIRRGVWKDWFRQWDLQJUDSHI UXLWRU0DQGDULQ
RUDQJHVIURPGD\VEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQ RUSRSS\VHHGV
EURFFROL%UXVVHOVVSURXWVSRPHJUDQDWHVWDUIUXLWRUFDIIHLQ H[DQWKLQHIURP
KRXUVEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQXQWLODIWHU GLVFKDUJHIURPWKH
FOLQLF3DUWLFLSDQWVZLOOEHLQVWUXFWHGQRWWRFRQVXPHDQ\RIW KHDERYHSURGXFWV
KRZHYHUDOORZDQFHIRUDQLVRODWHGVLQJOHLQFLGHQWDOFRQVXPSWLR QPD\EH
HYDOXDWHGDQGDSSURYHGE\WKHVWXG\,QYHVWLJDWRUEDVHGRQWKHS RWHQWLDOIRU
LQWHUDFWLRQZLWKWKHVWXG\GUXJ
6XEMHFWPXVWQRWHQJDJHLQVWUHQXRXVH[HUFLVHIURPKRXUVSUL RUWRWKHILUVWGRVH
RIVWXG\PHGLFDWLRQXQWLODIWHUGLVFKDUJHIURPWKHFOLQLF
0DOHVXEMHFWVPXVWQRWGRQDWHVSHUPWKURXJKRXWWUHDWPHQWDQGIR UDWOHDVW
ZHHNVDIWHUWKHODVWGRVHRIWULDOPHGLFDWLRQRUGLVFRQWLQXD WLRQIURPWULDO
PHGLFDWLRQLQFDVHRISUHPDWXUHGLVFRQWLQXDWLRQ
&RQWUDFHSWLRQ5HTXLUHPHQWV
)HPDOHVXEMHFWVPXVWSODQQRWWRFRQFHLYHWKURXJKRXWWUHDWPHQW DQGIRUDWOHDVWZHHN
DIWHUWKHODVWGRVHRIWULDOPHGLFDWLRQRUGLVFRQWLQXDWLRQIURP WULDOPHGLFDWLRQLQFDVHRI
SUHPDWXUHGLVFRQWLQXDWLRQ
0DOHVXEMHFWVPXVWSODQQRWWRFRQFHLYHRUGRQDWHVSHUPWKURXJK RXWWUHDWPHQWDQGIRU
DWOHDVWZHHNVDIWHUWKHODVWGRVHRIWULDOPHGLFDWLRQRUGL VFRQWLQXDWLRQIURPWULDO
PHGLFDWLRQLQFDVHRISUHPDWXUHGLVFRQWLQXDWLRQ
6XEMHFWVPXVWEHRIQRQFKLOGEHDULQJSRWHQWLDOGHILQHGDV
x0DOHRUIHPDOHVXEMHFWVLVQRWKHWHURVH[XDOO\DFWLYHRUSUDFW LFHVVH[XDO
DEVWLQHQFH
x)HPDOHVXEMHFWVRUPDOHVXEMHFWVZLWKDIHPDOHVH[XDOSDUWQHU ELODWHUDO
RRSKRUHFWRP\ELODWHUDOWXEDOOLJDWLRQDQGRUK\VWHUHFWRP\Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 20
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJHx)HPDOHVXEMHFWVSRVWPHQRSDXVDOZLWKDPHQRUUKHDIRUDWOHDVW\ HDUSULRUWRWKH
ILUVWGRVHZLWKVHUXPIROOLFOHVWLPXODWLQJKRUPRQH)6+OHYHOV FRQVLVWHQWZLWK
SRVWPHQRSDXVDOVWDWXVDWVFUHHQLQJ
x0DOHVXEMHFWRUIHPDOHSDUWLFLSDQWPDOHVH[XDOSDUWQHU±YDVHFW RPL]HGRUKDVKDG
ELODWHUDORUFKLGHFWRP\PLQLPDOO\WKUHHPRQWKVSULRUWRVFUHHQLQ J
2U
%HZLOOLQJWRXVHDQHIIHFWLYHPHWKRGRIELUWKFRQWUROGHILQHG DV
x0DOHVXEMHFWVZLWKDIHPDOHVH[XDOSDUWQHUGRXEOHEDUULHUPHWK RGRUKRUPRQH
EDVHGFRQWUDFHSWLYHVRUDQLQWUDXWHULQHGHYLFHIRUWKHIHPDOH SDUWQHU
x)HPDOHVXEMHFWVGRXEOHEDUULHUPHWKRGZKLFKFDQLQFOXGHDPDOH FRQGRP
GLDSKUDJPFHUYLFDOFDSRUIHPDOHFRQGRPRU
x)HPDOHVXEMHFWVEDUULHUPHWKRGFRPELQHGZLWKKRUPRQHEDVHGFRQ WUDFHSWLYHVRU
DQLQWUDXWHULQHGHYLFH
1RWH+RUPRQHEDVHGFRQWUDFHSWLRQDORQHPD\QRWEHUHOLDEOHZKH QWDNLQJWKHVWXG\
GUXJVWKHUHIRUHKRUPRQHEDVHGFRQWUDFHSWLYHVDORQHFDQQRWEH XVHGE\IHPDOH
VXEMHFWVWRSUHYHQWSUHJQDQF\
6FUHHQLQJ
7KHLQIRUPHGFRQVHQWGRFXPHQWVZLOOEHGLVFXVVHGZLWKHDFKSRWH QWLDOSDUWLFLSDQWDQG
HDFKLQGLYLGXDOZLOOVLJQDQLQIRUPHGFRQVHQWGRFXPHQWIRUWKH VWXG\EHIRUHDQ\
VWXG\VSHFLILFSURFHGXUHVEHLQJSHUIRUPHG
(DFKSRWHQWLDOVWXG\SDUWLFLSDQWZLOOKDYHWKHIROORZLQJDVVHVV PHQWVE\WKH,QYHVWLJDWRU
RUGHVLJQHHZLWKLQGD\VEHIRUHVWXG\VWDUW
x0HGLFDOKLVWRU\DQGGHPRJUDSKLFGDWDLQFOXGLQJVH[DJHUDFH HWKQLFLW\
ERG\ZHLJKWNJKHLJKWFP%0,NJPDQGVPRNLQJKDELWV
x3K\VLFDOH[DPLQDWLRQ
x9LWDOVLJQV
x(&*
x&OLQLFDOODERUDWRU\WHVWV
x6HURORJ\WHVWV
x8ULQHWHVWIRUGUXJVRIDEXVHDOFRKRODQGFRWLQLQH
x6HUXPSUHJQDQF\WHVWDOOIHPDOHVXEMHFWV
x)6+WHVW3RVWPHQRSDXVDOIHPDOHVGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 21
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJH2QO\PHGLFDOO\KHDOWK\VXEMHFWVZLWKFOLQLFDOO\DFFHSWDEOHODER UDWRU\SURILOHVDQG(&*V
ZLOOEHHQUROOHGLQWKHVWXG\
 678'<352&('85(6 6XEMHFW$VVLJQPHQW
7ZRSDQHOVRIKHDOWK\PDOHDQGIHPDOHVXEMHFWVSDUWLFLSDQWVS HUSDQHOZLOOEH
GRVHGLQWKLVVWXG\7KHVDPSOHVL]HLVQRWEDVHGRQVWDWLVWLFD OFRQVLGHUDWLRQV7KH
QXPEHURIVXEMHFWVSODQQHGIRUHQUROOPHQWLVFRQVLGHUHGVXIILFLHQ WWRDFKLHYHWKHVWXG\
REMHFWLYHV
6XEMHFWVZLOOEHUDQGRPL]HGWRDSDQHODQGWKHWZRSDQHOVZLOO EHLQYHVWLJDWHG
FRQFXUUHQWO\$GGLWLRQDOO\VXEMHFWVLQHDFKSDQHOZLOOEHUDQGR PL]HGDFFRUGLQJWRWKH
VDPHVHTXHQFHSHULRG:LOOLDPVGHVLJQLQZKLFKHDFKSDUWLFL SDQWZLOOUHFHLYHIRXU
VLQJOHGRVHWUHDWPHQWV
7KHPD[LPXPGXUDWLRQRIWKHVWXG\IURPVFUHHQLQJWRVWXG\H[LW ZLOOEHDSSUR[LPDWHO\
GD\V
7KLVLVDQRSHQODEHOVWXG\ZLWKRXWWUHDWPHQWEOLQGLQJ
 &KHFN,Q3URFHGXUHV
$WFOLQLFFKHFNLQ'D\DOOVXEMHFWVZLOOEHHYDOXDWHGWRFRQILUP WKH\FRQWLQXHWR
PHHWDOOWKHLQFOXVLRQFULWHULD 6HFWLRQ DQGQRQHRIWKHH[FOXVLRQFULWHULD
6HFWLRQ 
$XULQHVDPSOHZLOOEHFROOHFWHGIURPDOOVXEMHFWVDWVWXG\FKH FNLQWRVFUHHQIRUGUXJV
RIDEXVHFRWLQLQHDQGDOFRKRO,IDWDQ\WLPHDQDOFRKROGUX JRUFRWLQLQHWHVWLV
SRVLWLYHWKHVXEMHFWZLOOEHGLVFRQWLQXHGIURPVWXG\SDUWLFLSD WLRQ
6XEMHFWVRIFKLOGEHDULQJSRWHQWLDOZLOOEHDVNHGWRFRQILUPWKD WWKH\VWLOODGKHUHWRWKH
FRQWUDFHSWLYHFULWHULD 6HFWLRQ (DFKVXEMHFW¶VUHVSRQVHZLOOEHGRFXPHQWHG
$EORRGVDPSOHZLOOEHFROOHFWHGIURPDOOIHPDOHVXEMHFWVIRUDV HUXPSUHJQDQF\WHVW
7KLVWHVWPXVWEHQHJDWLYHIRUWKHVXEMHFWWRFRQWLQXHVWXG\SD UWLFLSDWLRQ
$QDEEUHYLDWHGSK\VLFDOH[DPLQDWLRQZLOOEHSHUIRUPHGLQFOXGLQJ PHDVXUHPHQWRI
ZHLJKW
%ORRGDQGXULQHZLOOEHFROOHFWHGIRUFOLQLFDOODERUDWRU\WHVWV KHPDWRORJ\FKHPLVWU\
DQGXULQDO\VLV
9LWDOVLJQVEORRGSUHVVXUHSXOVHWHPSHUDWXUHUHVSLUDWLRQUD WHDQGSXOVHR[LPHWU\
ZLOOEHPHDVXUHGDQGDVLQJOHOHDG(&*SHUIRUPHG
$Q\FKDQJHVWRPHGLFDOKLVWRU\DQGRUFRQFRPLWDQWPHGLFDWLRQZL OOEHUHFRUGHGGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 22
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH&RQILQHPHQW
6XEMHFWVZLOOEHDGPLWWHGWRWKHUHVHDUFKFHQWHUDWDQDSSURSUL DWHWLPHWKHGD\EHIRUHWKH
ILUVWVWXG\GUXJDGPLQLVWUDWLRQLQRUGHUWRHQVXUHDPLQLPXP KRXURYHUQLJKWIDVW
6XEMHFWVZLOOEHFRQILQHGLQWKHIDFLOLW\IURPFKHFNLQ'D\ XQWLOFRPSOHWLRQRIWKH
GD\SRVWGRVHSURFHGXUHVLQ3HULRG6WXG\'D\DQGUHWXU QIRUDIROORZXSVDIHW\
YLVLWRQ'D\
)DVWLQJ0HDOV%HYHUDJHV
)DVWLQJ0HDOV
3DQHOV	
$QRSWLRQDOPHDORUVQDFNZLOOEHVHUYHGWKHHYHQLQJRIHDFKFK HFNLQ$OOVXEMHFWVZLOO
IDVWIRUDWOHDVWKRXUVDIWHUHDFKGRVH6WDQGDUGPHDOVZLOO EHSURYLGHGDW
DSSUR[LPDWHO\DQGKRXUVDIWHUHDFKGUXJDGPLQLVWUDWLRQDQG DWDSSURSULDWHWLPHV
WKHUHDIWHU0HDOVQDFNPHQXVZLOOEHWKHVDPHIRUDOOVWXG\SHU LRGV
6XEMHFWPXVWQRWFRQVXPHEHYHUDJHVDQGIRRGVFRQWDLQLQJDOFRKRO JUDSHIUXLWSRSS\
VHHGVEURFFROL%UXVVHOVVSURXWVSRPHJUDQDWHVWDUIUXLWFKD UJULOOHGPHDWRU
FDIIHLQH[DQWKLQHIURPKRXUVEHIRUHWKHILUVWGRVHRIVWXG\ PHGLFDWLRQXQWLOWKHHQG
RIVWXG\YLVLW6XEMHFWVZLOOEHLQVWUXFWHGQRWWRFRQVXPHDQ\ RIWKHDERYHSURGXFWV
KRZHYHUDOORZDQFHIRUDQLVRODWHGVLQJOHLQFLGHQWDOFRQVXPSWLR QPD\EHHYDOXDWHGDQG
DSSURYHGE\WKHVWXG\LQYHVWLJDWRUEDVHGRQWKHSRWHQWLDOIRUL QWHUDFWLRQZLWKWKHVWXG\
GUXJ
3DQHOIHG
6XEMHFWVLQ3DQHOZLOOEHUHTXLUHGWRIDVWIRUDWOHDVWKR XUVEHIRUHFRQVXPLQJD
UHTXLUHG)'$VWDQGDUGKLJKIDWKLJKFDORULHEUHDNIDVW6XEMHFW VZLOOUHFHLYHWKH
EUHDNIDVWWREHJLQPLQXWHVEHIRUHVFKHGXOHGDGPLQLVWUDWLRQR IWKHGRVHDQGWRHQG
ODVWELWHWDNHQZLWKLQPLQXWHVEHIRUHGRVLQJ7KHVXEMHFWV ZLOOIDVWIRUKRXUV
WKHUHDIWHU7KHIROORZLQJKLJKIDWDSSUR[LPDWHO\RIWRWDO FDORULFFRQWHQWRIWKH
PHDOKLJKFDORULHDSSUR[LPDWHO\FDORULHVEUHDNIDVWZLO OEHLQJHVWHGPLQXWHV
EHIRUHDGPLQLVWUDWLRQRIWKHGUXJ
HJJVIULHGLQEXWWHU
VWULSVRIEDFRQVOLFHVRIWRDVWZLWKEXWWHURXQFHVRIKDVKEURZQSRWDWRHV
RXQFHVRIZKROHPLON
7KLVPHDOFRQWDLQVDSSUR[LPDWHO\SURWHLQFDORULHVFDUE RK\GUDWHFDORULHVDQG
IDWFDORULHV$QHTXLYDOHQWPHDOPD\EHVXEVWLWXWHGZLW KGRFXPHQWDWLRQRIWKH
PHQXDQGFDORULFFRQWHQWV7KHDPRXQWFRQVXPHGE\VXEMHFWVZLOO EHUHFRUGHGGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 23
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH3DQHOIDVWHG
6XEMHFWVLQ3DQHOZLOOEHUHTXLUHGWRIDVWIRUDWOHDVWKR XUVEHIRUHGRVLQJ
%HYHUDJHV
([FHSWIRUWKHURRPWHPSHUDWXUHZDWHUSURYLGHGZLWKWKHVWXG\W UHDWPHQWQRZDWHUPD\
EHFRQVXPHGIRUKRXUEHIRUHHDFKGRVHWKURXJKKRXUDIWHUHD FKGRVH$WRWKHU
WLPHVVXEMHFWVZLOOEHHQFRXUDJHGWRGULQNZDWHUDGOLELWXP
'UXJ$GPLQLVWUDWLRQ
6XEMHFWVZLOOEHDGPLQLVWHUHG7UHDWPHQW$[PJWDEOHWXV LQJWKHLPPHGLDWH
UHOHDVHIRUPXODWLRQZLWKP/RIDPELHQWURRPWHPSHUDWXUHZD WHU6XEMHFWVPXVW
VZDOORZWKHWDEOHWLQWDFWLWVKRXOG127EHFUXVKHGRUFKHZHG 
6XEMHFWVZLOOEHDGPLQLVWHUHG7UHDWPHQW%[PJGLVSHUVLEO HWDEOHWVDVIROORZV
FOLQLFVWDIIZLOOGLVSHUVHHDFKWDEOHWLQP/RIDPELHQWURRP WHPSHUDWXUHZDWHU
ZKLFKVXEMHFWVZLOOVZDOORZ)ROORZLQJHDFKP/GRVHFOLQLF VWDIIZLOOWKHQULQVHWKH
VDPHFRQWDLQHUZLWKDQDGGLWLRQDOP/RIDPELHQWURRPWHPSHUD WXUHZKLFKWKH
VXEMHFWVZLOOVZDOORZ6XEMHFWVZLOOWKHQULQVHWKHLUPRXWKVDQ GVZDOORZDQDGGLWLRQDO
P/RIDPELHQWURRPWHPSHUDWXUHZDWHU
6XEMHFWVZLOOEHDGPLQLVWHUHG7UHDWPHQW&[PJGLVSHUVLEO HWDEOHWDVIROORZV
FOLQLFVWDIIZLOOGLVSHUVHWKHWDEOHWLQP/RIDPELHQWURRP WHPSHUDWXUHZDWHUZKLFK
VXEMHFWVZLOOVZDOORZ&OLQLFVWDIIZLOOWKHQULQVHWKHVDPHFR QWDLQHUZLWKDQDGGLWLRQDO
P/RIDPELHQWURRPWHPSHUDWXUHZDWHUZKLFKWKHVXEMHFWVZLO OVZDOORZ6XEMHFWV
ZLOOWKHQULQVHWKHLUPRXWKVDQGVZDOORZDQDGGLWLRQDOP/RI DPELHQWURRP
WHPSHUDWXUHZDWHU
6XEMHFWVZLOOEHDGPLQLVWHUHG7UHDWPHQW'[PJGLVSHUVLEO HWDEOHWDVIROORZV
FOLQLFVWDIIZLOOGLVSHUVHWKHWDEOHWLQP/RIDPELHQWURRP WHPSHUDWXUHZDWHUZKLFK
VXEMHFWVZLOOVZDOORZ&OLQLFVWDIIZLOOWKHQULQVHWKHVDPHFR QWDLQHUZLWKDQDGGLWLRQDO
P/RIDPELHQWURRPWHPSHUDWXUHZDWHUZKLFKWKHVXEMHFWVZLO OVZDOORZ6XEMHFWV
ZLOOWKHQULQVHWKHLUPRXWKVDQGVZDOORZDQDGGLWLRQDOP/RI DPELHQWURRP
WHPSHUDWXUHZDWHU
$GGLWLRQDOGHWDLOVZLOOEHSURYLGHGLQDVHSDUDWHPDQXDO)RUDOOWUHDWPHQWVDPRXWKFKHFNZLOOEHSHUIRUPHGLPPHGLDWHO\ DIWHUHDFKGRVHWR
HQVXUHWKDWWKHVWXG\GUXJZDVDSSURSULDWHO\VZDOORZHG$KDQG FKHFNZLOODOVREH
SHUIRUPHGDIWHU7UHDWPHQW$
7KHVXEMHFWVZLOOUHPDLQVHDWHGH[FHSWDVRWKHUZLVHUHTXLUHGI RUVWXG\SURFHGXUHVRU
SHUVRQDOQHHGVIRUWKHILUVWKRXUVDIWHUGRVLQJ6KRXOGWKH QHHGWRPRYHDERXWRFFXU
GXULQJWKHILUVWKRXUVDIWHUHDFKGRVHVXEMHFWVPD\EHHVFRU WHGWRVXFKSURFHGXUHVRU
DFWLYLWLHVE\UHVHDUFKSHUVRQQHODVGHHPHGPHGLFDOO\QHFHVVDU\ 6XEMHFWVZLOOQRWEHGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 24
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHDOORZHGWROLHGRZQH[FHSWDVGLUHFWHGE\FOLQLFDOVWDIIVHFRQ GDU\WR$(VIRUWKHILUVW
KRXUVDIWHUGRVLQJ
 %ORRG6DPSOLQJ3URFHVVLQJDQG6KLSPHQW
%ORRGVDPSOHVIRUDQDO\VLVRISUHWRPDQLGFRQFHQWUDWLRQVZLOOEHG UDZQMXVWEHIRUHHDFK
GUXJDGPLQLVWUDWLRQSUHGRVHDQGDW DQG
KRXUVDIWHUHDFKGRVH$WRWDORIP/[P/VDPSOHVZLOOE HFROOHFWHG
IURPHDFKVXEMHFWIRUSKDUPDFRNLQHWLFDQDO\VLV%ORRGVDPSOHVZLO OEHFROOHFWHGDV
GHWDLOHGLQ $SSHQGL[, 3KDUPDFRNLQHWLF6DPSOH&ROOHFWLRQ3URFHVVLQJDQG6KLSPHQW
,QVWUXFWLRQV
x%ORRGVDPSOHVFROOHFWHGXSWRDQGLQFOXGLQJKRXUVSRVWGRVHZ LWKLQPLQXWHV
RIVFKHGXOHGWLPHZLOOQRWEHFRQVLGHUHGGHYLDWLRQV
x%ORRGVDPSOHVFROOHFWHGDIWHUKRXUVSRVWGRVHZLWKLQPLQXWH VRIVFKHGXOHG
WLPHZLOOQRWEHFRQVLGHUHGGHYLDWLRQV
7DEOH $FFHSWDEOH3KDUPDFRNLQHWLF6DPSOLQJ7LPH:LQGRZV
,QYHVWLJDWLRQD QGH[DPLQDWLRQ$OORZDEOH7LPH:LQGRZ
3RVWGRVH
 KRXUV !KRXUV
3ODVPDVDPSOHFROOHFWLRQIRU
SKDUPDFRNLQHWLFDVVHVVPHQW  rPLQXWHV  rPLQXWHV  
,QDGGLWLRQDSSUR[LPDWHO\P/RIEORRGLQWRWDOZLOOEHFROO HFWHGGXULQJWKHVWXG\
IRUWKHFOLQLFDOODERUDWRU\HYDOXDWLRQVDWWKHWLPHSRLQWVVKRZQLQ 7DEOH7KHWRWDO
YROXPHRIEORRGFROOHFWHGIURPHDFKVXEMHFWLQHDFKWUHDWPHQWV HVVLRQZLOOQRWH[FHHG
DSSUR[LPDWHO\P/
$GGLWLRQDOEORRGPD\EHFROOHFWHGLIQHFHVVDU\IRUUHSHDWODERU DWRU\HYDOXDWLRQVRU
$(IROORZXS
 (QGRI6WXG\3URFHGXUHV
6XEMHFWVZLOOUHWXUQWRWKHFOLQLFIRUDIROORZXSVDIHW\YLVLWD SSUR[LPDWHO\GD\VDIWHU
WKHLUILQDOGRVHRIVWXG\PHGLFDWLRQ'XULQJWKLVYLVLWWKHIRO ORZLQJSURFHGXUHVZLOOEH
FRQGXFWHG
x%ORRGDQGXULQHZLOOEHFROOHFWHGIRUFOLQLFDOODERUDWRU\WHVWV KHPDWRORJ\
FKHPLVWU\DQGXULQDO\VLV
x9LWDOVLJQVEORRGSUHVVXUHSXOVHWHPSHUDWXUHUHVSLUDWLRQUD WHDQGSXOVH
R[LPHWU\
x6LQJOHOHDG(&*Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 25
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHx3K\VLFDOH[DPLQDWLRQ
x'UXJFRWLQLQHDQGDOFRKROWHVWLQJ
x8ULQHSUHJQDQF\WHVWDOOIHPDOHVXEMHFWV
x$Q\XSGDWHVWR$(VDQGRUFRQFRPLWDQWPHGLFDWLRQ
:KHQSRVVLEOHHQGRIVWXG\SURFHGXUHVZLOOEHSHUIRUPHGLQWKH HYHQWRIDVXEMHFW¶V
HDUO\WHUPLQDWLRQIURPWKHVWXG\
 6DIHW\0RQLWRULQJDQG3URFHGXUHV
 6DIHW\±$GYHUVH(YHQWV
6XEMHFWVZLOOEHLQVWUXFWHGWRLQIRUPWKHVWXG\SK\VLFLDQDQGR UUHVHDUFKSHUVRQQHORI
DQ\$(VWKDWRFFXUDWDQ\WLPHGXULQJWKHVWXG\6XEMHFWVZLOOE HPRQLWRUHGIRU$(V
IURPWKHVLJQLQJRIWKHLQIRUPHGFRQVHQWWKURXJKWKHIROORZXSYLVLW 
5HIHUWR6HFWLRQ IRUGHWDLOVUHJDUGLQJ$(UHSRUWLQJ
 6DIHW\±&OLQLFDO/DERUDWRU\(YDOXDWLRQV
x&OLQLFDOODERUDWRU\WHVWVKHPDWRORJ\VHUXPFKHPLVWU\DQGXULQ DO\VLVZLOOEH
SHUIRUPHGDWWKHWLPHSRLQWVVKRZQLQWKH(YHQWV6FKHGXOH 7DEOH
R+HPDWRORJ\KHPRJORELQKHPDWRFULWWRWDODQGGLIIHUHQWLDOOHXN RF\WHFRXQWUHG
EORRGFHOOFRXQWDQGSODWHOHWFRXQW
R6HUXPFKHPLVWU\DOEXPLQEORRGXUHDQLWURJHQFUHDWLQLQHWRWD OELOLUXELQ
DONDOLQHSKRVSKDWDVHDVSDUWDWHWUDQVDPLQDVHDODQLQHWUDQVDPLQ DVHVRGLXP
SRWDVVLXPFKORULGHODFWDWHGHK\GURJHQDVHFDOFLXPXULFDFLG JOXFRVHJDPPD
JOXWDP\OWUDQVIHUDVHDQGPDJQHVLXP
R8ULQDO\VLVS+VSHFLILFJUDYLW\SURWHLQJOXFRVHNHWRQHVEL OLUXELQEORRGQLWULWH
OHXNRF\WHHVWHUDVHDQGXURELOLQRJHQ,ISURWHLQRFFXOWEORRG QLWULWHRUOHXNRF\WH
HVWHUDVHYDOXHVDUHRXWRIUDQJHDPLFURVFRSLFH[DPLQDWLRQZLOO EHSHUIRUPHG
x6HURORJ\%ORRGZLOOEHWHVWHGIRUKHSDWLWLV%VXUIDFHDQWLJHQKH SDWLWLV&DQWLERG\
DQG+,9DWVFUHHQLQJ
x8ULQH'UXJ&RWLQLQHDQG$OFRKRO6FUHHQV8ULQHVDPSOHVZLOOEH WHVWHGIRUGUXJVRI
DEXVHDPSKHWDPLQHVEHQ]RGLD]HSLQHVEDUELWXUDWHVFDQQDELQRLG VFRFDLQHRSLDWHV
FRWLQLQHDQGDOFRKRODWVFUHHQLQJDQGFKHFNLQ
x)RUDOOIHPDOHVXEMHFWVDVHUXPSUHJQDQF\WHVWDWVFUHHQLQJDQG FKHFNLQDQGDXULQH
SUHJQDQF\WHVWDWWKHIROORZXSYLVLW
x)ROOLFOHVWLPXODWLQJKRUPRQHSRVWPHQRSDXVDOIHPDOHVDWVFUHHQ LQJGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 26
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJH$&OLQLFDO/DERUDWRU\,PSURYHPHQW$PHQGPHQWV &/,$FHUWLILHGODERUDWRU\ZLOO
SHUIRUPDOOFOLQLFDOODERUDWRU\WHVWVIRUWKLVVWXG\
 6DIHW\±9LWDO6LJQV
9LWDOVLJQVEORRGSUHVVXUHSXOVHUDWHUHVSLUDWLRQUDWHWHPS HUDWXUHDQGSXOVH
R[LPHWU\ZLOOEHPHDVXUHGDWWKHWLPHSRLQWVVKRZQLQWKH(YHQWV 6FKHGXOH 7DEOH
%RWKEORRGSUHVVXUHDQGKHDUWUDWHSXOVHVKRXOGEHFDSWXUHGV LPXOWDQHRXVO\%ORRG
SUHVVXUHDQGKHDUWUDWHVKRXOGEHPHDVXUHGDIWHUSDUWLFLSDQWVDU HLQDVHDWHGSRVLWLRQIRU
DWOHDVWPLQXWHVDQGWKHQDJDLQDIWHUVWDQGLQJIRUPLQXWHH [FHSWZKHQWKH\DUH
VXSLQHRUVHPLUHFOLQHGEHFDXVHRIVWXG\SURFHGXUHVDQGRUDGYH UVHHYHQWVRUDV
GHHPHGQHFHVVDU\E\WKH,QYHVWLJDWRU
3UHGRVHYLWDOVLJQVZLOOEHDVVHVVHGE\WKH3ULQFLSDO,QYHVWLJD WRURUGHVLJQHHHJD
PHGLFDOO\TXDOLILHG6XE,QYHVWLJDWRUEHIRUHHDFKVWXG\GUXJDGP LQLVWUDWLRQ7KH
3ULQFLSDO,QYHVWLJDWRURUGHVLJQHHZLOOYHULI\WKHHOLJLELOLW\ RIHDFKVXEMHFWZLWK
RXWRIUDQJHYLWDOVLJQVDQGGRFXPHQWDSSURYDOEHIRUHGRVLQJ
$GGLWLRQDOYLWDOVLJQVPHDVXUHPHQWVPD\EHSHUIRUPHGDVGHHPHG PHGLFDOO\QHFHVVDU\
E\UHVHDUFKSHUVRQQHO$OOYLWDOVLJQVPHDVXUHPHQWVZLOOEHWDN HQDIWHUWKHVXEMHFWKDV
FRPSOHWHGDPLQLPXPPLQXWHVLW
 6DIHW\±3K\VLFDO([DPLQDWLRQV
$IXOOSK\VLFDOH[DPLQDWLRQZLOOEHSHUIRUPHGDWVFUHHQLQJ$QDE EUHYLDWHGSK\VLFDO
H[DPLQDWLRQZLOOEHSHUIRUPHGDWFKHFNLQ'D\DQGDWHQGRI VWXG\HDUO\
WHUPLQDWLRQ+HLJKWZLOORQO\EHFROOHFWHGDWVFUHHQLQJ
 6DIHW\±(OHFWURFDUGLRJUDPV
$VLQJOHOHDG(&*ZLOOEHSHUIRUPHGDIWHUWKHVXEMHFWKDVEHH QLQVXSLQHSRVLWLRQ
IRUDPLQLPXPRIPLQXWHVDWVFUHHQLQJDQGRQ6WXG\'D\V DQG7KH\PXVW
EHSHUIRUPHGZLWKLQKRXUVSULRUWRGRVLQJDQGFRPSOHWHGPLQX WHVSULRUWRSUHGRVH
EORRGGUDZ(&*VZLOOEHSULQWHGDQGUHYLHZHGRQVLWHE\WKH3ULQ FLSDO,QYHVWLJDWRURU
GHVLJQHH
 2WKHU6DIHW\0HDVXUHV
0HGLFDOHPHUJHQF\SHUVRQQHOWUDLQHGLQDGYDQFHGFDUGLDFOLIHVXS SRUWZLOOEHRQVLWHWR
PRQLWRUVXEMHFWVGXULQJWKHFRQILQHPHQWSHULRGLQWKHUHVHDUFK FHQWHU(PHUJHQF\
PHGLFDOHTXLSPHQWLQFOXGLQJEXWQRWOLPLWHGWRLQWXEDWLRQHTXLS PHQWDQGSXOVH
R[LPHWU\VKDOOEHPDLQWDLQHGRQVLWHWRDGPLQLVWHUDSSURSULDWHP HGLFDOFDUHVKRXOGLWEH
UHTXLUHG
3URFHGXUHVZLOOEHFRPSOHWHGDVVSHFLILHGLQWKLVSURWRFROXQOHV VFRQWUDLQGLFDWHGGXHWR
DUHSRUWHG$(Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 27
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH$'9(56((9(176
7KH,QYHVWLJDWRURUDVXLWDEO\PHGLFDOO\TXDOLILHGGHVLJQHHDUH UHVSRQVLEOHIRUHOLFLWLQJ
DGYHUVHHYHQWVE\REVHUYLQJDQGTXHVWLRQLQJWKHVXEMHFWDQGUHF RUGLQJDOODGYHUVH
HYHQWVREVHUYHGE\KLPKHURUUHSRUWHGE\WKHVXEMHFWGXULQJWK HWULDO
'HILQLWLRQV
$GYHUVH(YHQW
$Q\XQWRZDUGPHGLFDORFFXUUHQFHLQDFOLQLFDOLQYHVWLJDWLRQSDU WLFLSDQWWHPSRUDOO\
DVVRFLDWHGZLWKWKHXVHRIDWULDOWUHDWPHQWZKHWKHURUQRWFRQ VLGHUHGUHODWHGWRWULDO
WUHDWPHQW$QDGYHUVHHYHQWFDQWKHUHIRUHEHDQ\XQIDYRUDEOHDQ GXQLQWHQGHGVLJQ
LQFOXGLQJDQDEQRUPDOODERUDWRU\ILQGLQJV\PSWRPRUGLVHDVH QHZRUH[DFHUEDWHG
WHPSRUDOO\DVVRFLDWHGZLWKWKHXVHRIDWULDOWUHDWPHQWZKHWKH URUQRWUHODWHGWRWKHWULDO
WUHDWPHQW
6HULRXV$GYHUVH(YHQW
$Q\XQWRZDUGPHGLFDORFFXUUHQFHWKDWDWDQ\GRVH
x5HVXOWVLQGHDWK
x,VOLIHWKUHDWHQLQJDQ\HYHQWLQZKLFKWKHSDUWLFLSDQWZDVDW ULVNRIGHDWKDWWKHWLPH
RIWKHHYHQWLWGRHVQRWUHIHUWRDQHYHQWZKLFKK\SRWKHWLFDO O\PLJKWKDYHFDXVHG
GHDWKLILWZHUHPRUHVHYHUH
x5HTXLUHVLQSDWLHQWKRVSLWDOL]DWLRQRUSURORQJDWLRQRIH[LVWLQJ KRVSLWDOL]DWLRQ,Q
JHQHUDOKRVSLWDOL]DWLRQVLJQLILHVWKDWWKHSDUWLFLSDQWKDVEHH QGHWDLQHGXVXDOO\
LQYROYLQJDWOHDVWDQRYHUQLJKWVWD\DWWKHKRVSLWDORUHPHUJH QF\ZDUGIRU
REVHUYDWLRQDQGRUWUHDWPHQWWKDWZRXOGQRWKDYHEHHQDSSURSULD WHLQWKH
SK\VLFLDQ¶VRIILFHRURXWSDWLHQWVHWWLQJ&RPSOLFDWLRQVWKDWRF FXUGXULQJ
KRVSLWDOL]DWLRQDUH$(V,IDFRPSOLFDWLRQSURORQJVKRVSLWDOL]D WLRQRUIXOILOOVDQ\
RWKHUVHULRXVFULWHULDWKHHYHQWLVVHULRXV:KHQLQGRXEWDV WRZKHWKHU
³KRVSLWDOL]DWLRQ´RFFXUUHGRUZDVQHFHVVDU\WKH$(VKRXOGEHF RQVLGHUHGVHULRXV
+RVSLWDOL]DWLRQIRUHOHFWLYHWUHDWPHQWRIDSUHH[LVWLQJFRQGLW LRQWKDWGLGQRWZRUVHQ
IURPEDVHOLQHLVQRWFRQVLGHUHGDQ$(
x5HVXOWVLQSHUVLVWHQWRUVLJQLILFDQWGLVDELOLW\LQFDSDFLW\WKH WHUPGLVDELOLW\PHDQVD
VXEVWDQWLDOGLVUXSWLRQRIDSHUVRQ¶VDELOLW\WRFRQGXFWQRUPDO OLIHIXQFWLRQV7KLV
GHILQLWLRQLVQRWLQWHQGHGWRLQFOXGHH[SHULHQFHVRIUHODWLYHO\ PLQRUPHGLFDO
VLJQLILFDQFHVXFKDVXQFRPSOLFDWHGKHDGDFKHQDXVHDYRPLWLQJ GLDUUKHDLQIOXHQ]D
DQGDFFLGHQWDOWUDXPDHJVSUDLQHGDQNOHZKLFKPD\LQWHUIHU HZLWKRUSUHYHQW
HYHU\GD\OLIHIXQFWLRQVEXWGRQRWFRQVWLWXWHDVXEVWDQWLDOGLV UXSWLRQ
x,VDFRQJHQLWDODQRPDO\ELUWKGHIHFWRUGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 28
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJHx,VDPHGLFDOO\LPSRUWDQWHYHQW
1RWH0HGLFDODQGVFLHQWLILFMXGJPHQWVKRXOGEHH[HUFLVHGLQG HFLGLQJZKLFKLVD
PHGLFDOO\LPSRUWDQWHYHQWWKDWPD\QRWEHLPPHGLDWHO\OLIHWKUH DWHQLQJRUUHVXOWLQ
GHDWKRUKRVSLWDOL]DWLRQEXWPD\MHRSDUGL]HWKHSDUWLFLSDQWRU PD\UHTXLUHPHGLFDORU
VXUJLFDOLQWHUYHQWLRQWRSUHYHQWRQHRIWKHRXWFRPHVOLVWHGDER YH([DPSOHVRIVXFK
HYHQWVDUHLQWHQVLYHWUHDWPHQWLQDQHPHUJHQF\URRPRUDWKRPH IRUDOOHUJLF
EURQFKRVSDVPEORRGG\VFUDVLDVRUFRQYXOVLRQVWKDWGRQRWUHVXO WLQKRVSLWDOL]DWLRQRU
WKHGHYHORSPHQWRIGUXJGHSHQGHQF\RUGUXJDEXVH$³VXVSHFWHG WUDQVPLVVLRQRI
LQIHFWLRXVDJHQWE\DPHGLFLQDOSURGXFW´LVDOVRFRQVLGHUHGDV HULRXVDGYHUVHHYHQW
XQGHUWKH6$(FULWHULRQ³2WKHUPHGLFDOO\LPSRUWDQWFRQGLWLRQ´ 
$WWULEXWLRQ&DXVDOLW\
$QDGYHUVHUHDFWLRQWKHQDWXUHRUVHYHULW\RIZKLFKLVQRWFRQ VLVWHQWZLWKWKH
DSSOLFDEOHSURGXFWLQIRUPDWLRQHJ,QYHVWLJDWRU¶V%URFKXUHI RUDQXQDSSURYHG
LQYHVWLJDWLRQDOSURGXFW
x7KHLQYHVWLJDWRULVREOLJDWHGWRDVVHVVWKHUHODWLRQVKLSEHWZHH QWULDOWUHDWPHQWDQG
HDFKRFFXUUHQFHRIHDFK$(6$(
x7KHLQYHVWLJDWRUZLOOXVHFOLQLFDOMXGJPHQWWRGHWHUPLQHWKHUH ODWLRQVKLS
x$OWHUQDWLYHFDXVHVVXFKDVXQGHUO\LQJGLVHDVHVFRQFRPLWDQW WKHUDS\DQGRWKHU
ULVNIDFWRUVDVZHOODVWKHWHPSRUDOUHODWLRQVKLSRIWKHHYHQW WRWULDOWUHDWPHQW
DGPLQLVWUDWLRQZLOOEHFRQVLGHUHGDQGLQYHVWLJDWHG
x7KHLQYHVWLJDWRUZLOODOVRFRQVXOWWKH,QYHVWLJDWRU¶V%URFKXUH DQGRU3URGXFW
,QIRUPDWLRQIRUPDUNHWHGSURGXFWVLQKLVKHUDVVHVVPHQW
x)RUHDFK$(6$(WKHLQYHVWLJDWRUPXVWGRFXPHQWLQWKHPHGLFDO QRWHVWKDWKHVKH
KDVUHYLHZHGWKH$(6$(DQGKDVSURYLGHGDQDVVHVVPHQWRIFDXVD OLW\
x7KHUHPD\EHVLWXDWLRQVLQZKLFKDQ6$(KDVRFFXUUHGDQGWKHL QYHVWLJDWRUKDV
PLQLPDOLQIRUPDWLRQWRLQFOXGHLQWKHLQLWLDOUHSRUWWRWKH6SR QVRUGHVLJQHH
+RZHYHULWLVYHU\LPSRUWDQWWKDWWKHLQYHVWLJDWRUDOZD\VPDNH DQDVVHVVPHQWRI
FDXVDOLW\IRUHYHU\HYHQWEHIRUHWKHLQLWLDOWUDQVPLVVLRQRIWK H6$(GDWDWRWKH
6SRQVRUGHVLJQHH
x7KHLQYHVWLJDWRUPD\FKDQJHKLVKHURSLQLRQRIFDXVDOLW\LQOLJ KWRIIROORZXS
LQIRUPDWLRQDQGVHQGD6$(IROORZXSUHSRUWZLWKWKHXSGDWHGFD XVDOLW\
DVVHVVPHQW 
7DEOH $GYHUVH(YHQW$WWULEXWLRQ&DXVDOLW\5DWLQJV

5HODWHGQHVV5DWLQJ  'HILQLWLRQ 
1RW5HODWHG $QDGYHUVHHYHQWZKLFKLVQRWUHODWHGWRWKHXVHRIWKHGUXJGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 29
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJH5HODWHGQHVV5DWLQJ 'HILQLWLRQ
8QOLNHO\ $QDGYHUVHHYHQWIRUZKLFKDQDOWHUQDWLYHH[SODQDWLRQLVPRUHO LNHO\HJ
FRQFRPLWDQWGUXJVRUFRQFRPLWDQWGLVHDVHV DQGRUWKHUHODWLRQVKLSLQWLPH
VXJJHVWVWKDWDFDXVDOUHODWLRQVKLSLVXQOLNHO\
3RVVLEOH $QDGYHUVHHYHQWZKLFKPLJKWEHGXHWRWKHXVHRIWKHGUXJ$ QDOWHUQDWLYH
H[SODQDWLRQHJFRQFRPLWDQWGUXJVRUFRQFRP LWDQWGLVHDVHVLVLQFRQFOXVLYH
7KHUHODWLRQVKLSLQWLPHLVUHDVRQDEOHWKHUHIRUHWKHFDXVDOU HODWLRQVKLSFDQQRWEH
H[FOXGHG
3UREDEOH $QDGYHUVHHYHQWZKLFKPLJKWEHGXHWRWKHXVHRIWKHGUXJ7 KHUHODWLRQVKLSLQ
WLPHLVVXJJHVWLYHHJFRQILUP HGE\GHFKDOOHQJH$QDOWHUQDWLYHH[ SODQDWLRQLV
OHVVOLNHO\HJFRQFRPLWDQWGUXJVRUFRQFRPLWDQWGLVHDVHV 
&HUWDLQ $QDGYHUVHHYHQWZKLFKLVOLVWHGDVDSRVVLEOHDGYHUVHUHDFWLR QDQGFDQQRWEH
UHDVRQDEO\H[SODLQHGE\DQDOWHUQDWLYHH[SODQDWLRQHJ FRQFRPLWDQWGUXJVRU
FRQFRPLWDQWGLVHDVHV
7DEOH 'HILQLWLRQVIRU$GYHUVH(YHQW6HYHULW\*UDGLQJV
*UDGH 6HYHULW\5DWLQJ 'HILQLWLRQ
*5$'( 0LOG7UDQVLHQWRUPLOGGLVFRPIRUWKRXUVQRPHGLFDO
LQWHUYHQWLRQWKHUDS\UHTXLUHG
*5$'( 0RGHUDWH0LOGWRPRGHUDWHOLPLWDWLRQLQDFWLYLW\VRPHDVVLVWDQFHPD\EH
QHHGHGQRRUPLQLPDOPHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHG
*5$'( 6HYHUH0DUNHGOLPLW DWLRQLQDFWLYLW\VRPHDVVLVWDQFHXVXDOO\UHTXLUHG
PHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHGKRVSLWDOL]DWLRQVSRVVLEO H
*5$'(3RWHQWLDOO\/LIH 
7KUHDWHQLQJ([WUHPHOLPLWDWLRQLQDFWLYLW\VLJQ LILFDQWDVVLVWDQFHUHTXLUHG
VLJQLILFDQWPHGLFDOLQWHUYHQWLRQW KHUDS\UHTXLUHGKRVS LWDOL]DWLRQRU
KRVSLFHFDUHSUREDEOH
6HH$SSHQGL[ IRUIXOO'0,'7R[LFLW\7DEOHV7KHDERYHUDWLQJVVKRXOGEHXVHG WR
HVWLPDWHWKHJUDGHIRUDEQRUPDOLWLHV127IRXQGHOVHZKHUHLQWKH 7R[LFLW\7DEOHV/DE
UHVXOWVZLWKLQWKHWHVWLQJIDFLOLW\¶VQRUPDOUDQJHZLOOQRWEHF RQVLGHUHG$(VZKHQ
UHIHUHQFHGWRWKH'0,'DVVHVVPHQWJUDGLQJVFDOH $SSHQGL[ 
/DERUDWRU\DEQRUPDOLWLHVDQGFDUGLRYDVFXODUILQGLQJVRIK\SHUWH QVLRQRUK\SRWHQVLRQ
*UDGHRUDERYHRQWKH'0,'WR[LFLW\WDEOHVZLOOEHFRQVLGHUHG $(V
 5HSRUWLQJ
 $GYHUVH(YHQW
$GYHUVH(YHQWVZLOOEHFROOHFWHGE\WKH,QYHVWLJDWRURUTXDOLILH GGHVLJQHHVIURPWKH
WLPHDVXEMHFWVLJQVWKH,QIRUPHG&RQVHQW)RUPWKURXJKWKHIROO RZXSSKRQHFDOOV
'D\GD\$Q\$(VHULRXVRUQRQVHULRXVREVHUYHGE\WKH ,QYHVWLJDWRURUDGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 30
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJHVXLWDEO\PHGLFDOO\TXDOLILHGGHVLJQHHRUUHSRUWHGE\WKHVXEMH FWZLOOEHUHFRUGHGRQWKH
$GYHUVH(YHQW&DVH5HSRUW)RUP7KH,QYHVWLJDWRUZLOOUHYLHZHD FK$(DQGDVVHVVLWV
UHODWLRQVKLSWRGUXJWUHDWPHQWEDVHGRQDOODYDLODEOHLQIRUPDWL RQDWWKHWLPHRIWKH
FRPSOHWLRQRIWKH&5)7KHIROORZLQJLQIRUPDWLRQZLOOEHUHFRUG HGIRUHDFK$GYHUVH
(YHQWUHSRUWHG
x'LDJQRVLVRIWKH$(LISRVVLEOH,QWKHFDVHZKHUHDQRYHUDOO GLDJQRVLVFDQQRWEH
PDGHHDFKVSHFLILFVLJQDQGRUV\PSWRPZLOOEHUHFRUGHGDVLQG LYLGXDO$(V
x'DWHRIRQVHW
x6WRSGDWHZLWKGXUDWLRQLIDSSOLFDEOH
x6HYHULW\
x$FWLRQWDNHQZLWK,03
x2WKHUDFWLRQWDNHQ
x2XWFRPH
x5HODWLRQVKLSWR,03
x2FFXUUHQFH
x6HULRXVQHVV
6HULRXV$GYHUVH(YHQW5HSRUWLQJ
7KH,QYHVWLJDWRURUGHVLJQHHZLOOQRWLI\WKHDSSURSULDWH6SRQVR UFRQWDFWLPPHGLDWHO\
DIWHUWKH6$(GHWHFWLRQREVHUYDWLRQRUUHSRUWRIRFFXUUHQFH UHJDUGOHVVRIWKH
UHODWLRQVKLSWRWHVWDUWLFOH7KH6SRQVRUFRQWDFWLQIRUPDWLRQ IRU6$(UHSRUWLQJLV
SURYLGHGEHORZ
33'39*SKDUPDFRYLJLODQFHVHUYLFHSURYLGHUIRU7%$OOLDQFH
(PDLOUWSVDIHW\#SSGLFRP6DIHW\+RWOLQH6DIHW\)D[1XPEHU
$QG
$QWRQLR7RQ\/RPEDUGL0'
*OREDO$OOLDQFHIRU7%'UXJ'HYHORSPHQW
:DOO6WUHHWWK)ORRU
1HZ<RUN1<8QLWHG6WDWHVRI$PHULFD7HOHSKRQH0RELOH)DFVLPLOH
(PDLO$QWRQLR/RPEDUGL&RQVXOWDQW#WEDOOLDQFHRUJ
7KHVH6$(UHSRUWVPXVWFRQWDLQWKHIROORZLQJLQIRUPDWLRQ
$6WXG\QDPHQXPEHUIRU(8DOVRWKH(XGUDFWQXPEHUGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 31
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH%6WXG\GUXJ
&,QYHVWLJDWRUGHWDLOVQDPHSKRQHID[HPDLO
'6XEMHFWQXPEHU
(6XEMHFWGHPRJUDSKLFV
)&OLQLFDOHYHQW
'HVFULSWLRQ
'DWHRIRQVHW
7UHDWPHQWGUXJGRVHGRVDJHIRUP
$GYHUVHHYHQWUHODWLRQVKLSWRVWXG\GUXJ
$FWLRQWDNHQUHJDUGLQJVWXG\GUXJLQGLUHFWUHODWLRQVKLSWRWKH $(
*,IWKH$(ZDVIDWDORUOLIHWKUHDWHQLQJ
+,IDSSOLFDEOHFDXVHRIGHDWKZKHWKHURUQRWWKHGHDWKZDVUHO DWHGWRVWXG\GUXJ
,,IDSSOLFDEOHDXWRSV\ILQGLQJVLIDYDLODEOH
$Q\QHZ6$(WKDWRFFXUVZLWKLQRQHPRQWKDIWHUWKHVWXG\SHULRG DQGLVFRQVLGHUHGWR
EHSRVVLEO\UHODWHGWRWKH,QYHVWLJDWLRQDO3URGXFW,3VKRXOG EHUHFRUGHGDQGUHSRUWHG
LPPHGLDWHO\WRWKH6SRQVRU
7KHSHUVRQUHVSRQVLEOHIRUWKHVWXG\VKDOOWDNHFDUHWKDWWKHV WXG\KDVEHHQFDUULHGRXW
LQDFFRUGDQFHZLWKSKDUPDFRYLJLODQFHORFDOUHJXODWLRQV
$OOVHULRXVHYHQWUHSRUWLQJZLOODGKHUHWR86&RGHRI)HGHUDO 5HJXODWLRQV
&)53DUWIRU,1'GUXJVDQG&)5IRUPDUNHW HGGUXJVGD\
DOHUWV7KH,QVWLWXWLRQDO5HYLHZ%RDUG,5%ZLOOEHQRWLILHG RIWKHDOHUWUHSRUWVSHU
)RRGDQG'UXJ$GPLQLVWUDWLRQ)'$UHJXODWLRQV
$OO$(VLQFOXGLQJ6$(VZLOOEHIROORZHGWRUHVROXWLRQZKHQSR VVLEOH$OO$(VDQG
WUHDWPHQWDGPLQLVWHUHGZLOOEHUHFRUGHGRQWKHFDVHUHSRUWIRUP &5)
7KH6SRQVRUZLOOEHUHVSRQVLEOHIRUSURFHVVLQJDQGUHSRUWLQJDQ \6$(VDQGWKHLU
UHOHYDQWXSGDWHVWRWKH)'$RURWKHUDSSOLFDEOHUHJXODWRU\DJH QF\
)ROORZXSRI$GYHUVH(YHQWV
$OO$(VZLOOEHIROORZHGXQWLO
x6DWLVIDFWRU\FOLQLFDOUHVROXWLRQRUVWDELOL]DWLRQRU
x(QGRIWKHIROORZXSSHULRGDQG
x$OOTXHULHVRQWKHVH$(VKDYHEHHQUHVROYHG
&HUWDLQORQJWHUP$(VFDQQRWEHIROORZHGXQWLOUHVROXWLRQZLWKL QWKHVHWWLQJRIWKLV
SURWRFRO,QWKHVHFDVHVIROORZXSZLOOEHWKHUHVSRQVLELOLW\ RIWKHWUHDWLQJSK\VLFLDQ
+RZHYHUWKLVZLOOKDYHWREHDJUHHGXSRQZLWKWKH6SRQVRU0HGL FDO0RQLWRUGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 32
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH7KHLQYHVWLJDWRULVREOLJDWHGWRSHUIRUPRUDUUDQJHIRUWKHFRQ GXFWRIVXSSOHPHQWDO
PHDVXUHPHQWVDQGRUHYDOXDWLRQVDVPHGLFDOO\LQGLFDWHGRUDVUH TXHVWHGE\6SRQVRURU
UHSUHVHQWDWLYHWRHOXFLGDWHWKHQDWXUHDQGRUFDXVDOLW\RIWKH $(RU6$(DVIXOO\DV
SRVVLEOH7KLVPD\LQFOXGHDGGLWLRQDOODERUDWRU\WHVWVRULQYHV WLJDWLRQV
KLVWRSDWKRORJLFDOH[DPLQDWLRQVRUFRQVXOWDWLRQZLWKRWKHUKHDO WKFDUHSURIHVVLRQDOV
,QYHVWLJDWRUVKRXOGFRQWDFWVSRQVRUGHVLJQHHWRGLVFXVVDSSURSU LDWHPHGLFDOIROORZXS
LIFRQVXOWDWLRQUHTXLUHG
,IDSDUWLFLSDQWGLHVGXULQJSDUWLFLSDWLRQLQWKHWULDORUGXUL QJDUHFRJQL]HGIROORZXS
SHULRGWKHLQYHVWLJDWRUZLOOSURYLGHVSRQVRUUHSUHVHQWDWLYHZL WKDFRS\RIDQ\SRVW
PRUWHPILQGLQJVLQFOXGLQJKLVWRSDWKRORJ\
1HZRUXSGDWHGLQIRUPDWLRQRQDQ6$(ZLOOEHUHFRUGHGLQWKHRU LJLQDOO\FRPSOHWHG
&5)DQGVXEPLWWHGWRVSRQVRUZLWKLQKRXUVRIWKHLQIRUPDWLRQ EHFRPLQJNQRZQSHU
6$(UHSRUWLQJJXLGHOLQHV
3RVW7ULDO6HULRXV$GYHUVH(YHQWV
$Q\QHZ6$(VUHSRUWHGE\WKHVXEMHFWWRWKH,QYHVWLJDWRUWKDWR FFXUXSWRGD\VDIWHU
ODVWFRQWDFWDQGDUHGHWHUPLQHGE\WKH3ULQFLSDO,QYHVWLJDWRUW REHSRVVLEOHSUREDEOHRU
YHU\OLNHO\UHODWHGWRWKHXVHRIWKH,03ZLOOEHUHSRUWHGWR WKH6SRQVRU,5%DQG)'$
RQDQH[SHGLWHGEDVLVDVUHTXLUHGLQDFFRUGDQFHZLWKORFDOUHTX LUHPHQWVDQG,&+
JXLGHOLQHVIRU*&3
&OLQLFDO/DERUDWRU\$GYHUVH(YHQWV
&KDQJHVLQWKHUHVXOWVRIWKH&OLQLFDO/DERUDWRU\DVVHVVPHQWUH VXOWVZKLFKWKH
,QYHVWLJDWRUIHHOVDUHFOLQLFDOO\VLJQLILFDQWZLOOEHUHSRUWHG DVDGYHUVHHYHQWV,WLVWKH
,QYHVWLJDWRUV¶UHVSRQVLELOLW\WRUHYLHZWKHUHVXOWVRIDOOODER UDWRU\WHVWVDVWKH\EHFRPH
DYDLODEOH7KLVUHYLHZPXVWEHGRFXPHQWHGE\WKH,QYHVWLJDWRUV¶ GDWHGVLJQDWXUHRQWKH
ODERUDWRU\UHSRUW)RUHDFKDEQRUPDOODERUDWRU\WHVWUHVXOWWK H,QYHVWLJDWRUQHHGVWR
DVFHUWDLQDQGGRFXPHQWLIWKLVLVDFOLQLFDOO\VLJQLILFDQWFKDQ JHIURPEDVHOLQHIRUWKDW
LQGLYLGXDOSDUWLFLSDQW7KLVGHWHUPLQDWLRQKRZHYHUGRHVQRWQ HFHVVDULO\QHHGWREH
PDGHWKHILUVWWLPHDQDEQRUPDOYDOXHLVREVHUYHG7KH,QYHVWLJ DWRUPD\UHSHDWWKH
ODERUDWRU\WHVWRUUHTXHVWDGGLWLRQDOWHVWVWRYHULI\WKHUHVXO WVRIWKHRULJLQDOODERUDWRU\
WHVWV,IWKLVODERUDWRU\YDOXHLVGHWHUPLQHGE\WKH,QYHVWLJD WRUWREHDFOLQLFDOO\
VLJQLILFDQWFKDQJHIURPEDVHOLQHIRUWKDWSDUWLFLSDQWLWLVFR QVLGHUHGWREHDQDGYHUVH
HYHQW
'UXJ,QWHUDFWLRQ
,IWKH,QYHVWLJDWRUEHFRPHVDZDUHWKDWWKHVXEMHFWKDVH[SHULHQ FHGDGUXJLQWHUDFWLRQ
ZKLFKKDVUHVXOWHGLQDQDGYHUVHHYHQWLWZLOOEHUHFRUGHGDV DQDGYHUVHHYHQWGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 33
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH3UHJQDQF\
7KH,QYHVWLJDWRUZLOOLPPHGLDWHO\QRWLI\WKH6SRQVRURIDQ\SUH JQDQF\WKDWLV
GLVFRYHUHGGXULQJWKHFOLQLFDOWULDO3UHJQDQF\IRUPVZLOOEHF RPSOHWHGIRUDOO
SUHJQDQFLHVUHSRUWHGGXULQJWKHVWXG\RULQWKHGD\VDIWHUF RPSOHWLRQRIWKH,03,Q
DGGLWLRQWKH,QYHVWLJDWRUZLOOUHSRUWWRWKH6SRQVRUIROORZXS LQIRUPDWLRQUHJDUGLQJWKH
RXWFRPHRIWKHSUHJQDQF\LQFOXGLQJSHULQDWDODQGQHRQDWDORXWF RPH,QIDQWVVKRXOGEH
IROORZHGIRUPRQWKV
,ISUHJQDQF\LVVXVSHFWHGZKLOHWKHVXEMHFWLVUHFHLYLQJ,03W KH,03ZLOOEHZLWKKHOG
LPPHGLDWHO\XQWLOWKHUHVXOWRIWKHSUHJQDQF\WHVWLVNQRZQ, ISUHJQDQF\LVFRQILUPHG
WKH,03ZLOOEHSHUPDQHQWO\GLVFRQWLQXHGLQDQDSSURSULDWHPDQQ HUDQGWKHVXEMHFW
ZLWKGUDZQIURPWKHWULDO3URWRFROUHTXLUHGSURFHGXUHVIRUWULD OGLVFRQWLQXDWLRQDQG
IROORZXSZLOOEHSHUIRUPHGXQOHVVFRQWUDLQGLFDWHGE\WKHSUHJQ DQF\
,IWKH,QYHVWLJDWRUEHFRPHVDZDUHWKHIHPDOHSDUWQHURIDPDOH VXEMHFWEHFRPHV
SUHJQDQWGXULQJWKHVWXG\RULQWKHGD\VDIWHUWKHFRPSOHWLR QRI,03FRQVHQWZLOOEH
UHTXHVWHGIURPWKHIHPDOHSDUWQHUIRUFROOHFWLRQRILQIRUPDWLRQ RQKHUSUHJQDQF\
KLVWRU\DQGIRULQIRUPDWLRQRQWKHFXUUHQWSUHJQDQF\DQGELUWK 
*(1(5$/&216,'(5$7,216
%DVLF3ULQFLSOHV
7KLVUHVHDUFKZLOOEHFDUULHGRXWLQDFFRUGDQFHZLWKWKHSURWRF ROWKH,QWHUQDWLRQDO
&RXQFLOIRU+DUPRQLVDWLRQ,&+*XLGHOLQHIRU*RRG&OLQLFDO3U DFWLFH&RQVROLGDWHG
*XLGDQFH(DQGDSSOLFDEOHUHJXODWRU\UHTXLUHPHQWVVLQFOXG LQJFOLQLFDOUHVHDUFK
JXLGHOLQHVHVWDEOLVKHGE\WKH%DVLF3ULQFLSOHVGHILQHGLQWKH8 6&)53DUWV
DQGDQGWKHSULQFLSOHVHQXQFLDWHGLQWKH'HFODUDWLRQRI+HO VLQNLUHYLVHGYHUVLRQ
)RUWDOH]D
,QVWLWXWLRQDO5HYLHZ%RDUG
7KLVSURWRFROZLOOEHUHYLHZHGE\DQDSSURSULDWH,5%DQGVWXG\ HQUROOPHQWZLOOQRW
FRPPHQFHXQWLOWKH%RDUGKDVDSSURYHGWKHSURWRFRORUDPRGLILF DWLRQWKHUHRI7KH
%RDUGLVFRQVWLWXWHGDQGRSHUDWHVLQDFFRUGDQFHZLWKWKHSULQFL SOHVDQGUHTXLUHPHQWV
GHVFULEHGLQ&)53DUW
,QIRUPHG&RQVHQW
:ULWWHQLQIRUPHGFRQVHQWZLOOEHREWDLQHGIURPHDFKVXEMHFWEHI RUHSHUIRUPLQJDQ\
EDVHOLQHVWXG\VSHFLILFHYDOXDWLRQV7KHLQIRUPHGFRQVHQWGRFXP HQWLVSUHSDUHGE\WKH
,QYHVWLJDWRURUGHVLJQHHVXEMHFWWRUHYLHZDQGDSSURYDOE\WKH 6SRQVRUDQGIRUZDUGHG
WRDTXDOLILHG,5%IRUILQDOUHYLHZDQGDSSURYDO7KH,5%DSSUR YHGGRFXPHQWPXVW
FRQWDLQDWPLQLPXPWKHHLJKWEDVLFHOHPHQWVRILQIRUPHGFRQVH QW2QO\WKHPRVWGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 34
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHUHFHQWO\,5%DSSURYHG,QIRUPHG&RQVHQW'RFXPHQWPXVWEHXVHGWR FRQVHQW
SURVSHFWLYHVWXG\VXEMHFWV2QHFRS\RIWKHVLJQHGDQGGDWHGLQ IRUPHGFRQVHQW
GRFXPHQWZLOOEHJLYHQWRWKHVXEMHFWDQGWKHRULJLQDOUHWDLQHG E\WKH,QYHVWLJDWRUVLWH
 ,QGLFDWLRQVIRU6XEMHFW:LWKGUDZDO
6XEMHFWVZLOOEHIUHHWRZLWKGUDZDWDQ\WLPHIRUDQ\UHDVRQRU WKH\PD\EHZLWKGUDZQ
LIQHFHVVDU\WRSURWHFWWKHLUKHDOWKDQGVDIHW\RUWKHLQWHJUL W\RIWKHVWXG\GDWD
6XEMHFWVZKRDUHZLWKGUDZQIURPWKHVWXG\ZLOOQRWEHUHSODFHG6 XEMHFWVLQ3DQHO
IHGZKRGRQRWFRPSOHWHWKHUHTXLUHG)'$VWDQGDUGKLJKIDWK LJKFDORULHEUHDNIDVW
ZLOOEHZLWKGUDZQIURPWKDWVWXG\SHULRG
7KHILQDOUHSRUWZLOOLQFOXGHUHDVRQVIRUZLWKGUDZDOV,QWKHH YHQWRIDQHDUO\
WHUPLQDWLRQVXEMHFWVZLOOXQGHUJRWKHSURFHGXUHVGHVFULEHGLQ 6HFWLRQ 
 7HUPLQDWLRQRIWKH 6WXG\
7KH3ULQFLSDO,QYHVWLJDWRUUHVHUYHVWKHULJKWWRWHUPLQDWHWKH VWXG\LQWKHLQWHUHVWRI
VXEMHFWVDIHW\DQGZHOIDUH7KH6SRQVRUUHVHUYHVWKHULJKWWRWH UPLQDWHWKHVWXG\DWDQ\
WLPHIRUDGPLQLVWUDWLYHUHDVRQV
 'RFXPHQWDWLRQ
$OOGRFXPHQWVSHUWDLQLQJWRWKHVWXG\LQFOXGLQJDFRS\RIWKH DSSURYHGSURWRFROFRS\
RIWKHLQIRUPHGFRQVHQWGRFXPHQWDQG+HDOWK,QVXUDQFH3RUWDELOLW \DQG$FFRXQWDELOLW\
$FW+,3$$GRFXPHQWVFRPSOHWHG&5)VZKHUHDSSOLFDEOHGUXJ DFFRXQWDELOLW\DQG
UHWHQWLRQUHFRUGVDQGRWKHUVWXG\UHODWHGGRFXPHQWVZLOOEHUH WDLQHGLQWKHSHUPDQHQW
DUFKLYHVRIWKHVWXG\VLWH7KHVHZLOOEHDYDLODEOHIRULQVSHFWL RQDWDQ\WLPHE\WKH
6SRQVRURUWKH)'$3HU&)5UHFRUGUHWHQWLRQIRUWKLVVWX G\LVUHTXLUHGIRUD
SHULRGRIWZR\HDUVIROORZLQJWKHGDWHRQZKLFKWKLVVWXG\DJHQ WLVDSSURYHGE\WKH
)'$IRUWKHPDUNHWLQJSXUSRVHVWKDWZHUHWKHVXEMHFWRIWKLVLQ YHVWLJDWLRQRULIQR
DSSOLFDWLRQLVWREHILOHGRULIWKHDSSOLFDWLRQLVQRWDSSURYH GIRUVXFKLQGLFDWLRQXQWLO
WZR\HDUVIROORZLQJWKHGDWHRQZKLFKWKHHQWLUHVWXG\LVFRPSOH WHGWHUPLQDWHGRU
GLVFRQWLQXHGDQGWKH)'$LVQRWLILHG
6XEMHFWUHFRUGVZLOOEHNHSWSULYDWHH[FHSWZKHQRUGHUHGE\ODZ 7KHIROORZLQJ
LQGLYLGXDOVZLOOKDYHDFFHVVWRVWXG\VXEMHFWUHFRUGV3ULQFLSD O,QYHVWLJDWRUDQG
GHVLJQHHVVWXG\6SRQVRUPRQLWRUVDQGDXGLWRUVWKH)'$RWKHU JRYHUQPHQWRIILFHV
DQGWKH,5%
 7ULDO0RQLWRULQJ
6SRQVRUSHUVRQQHORUGHVLJQHHVZLOOEHUHVSRQVLEOHIRUPRQLWR ULQJWKHVWXG\WRHQVXUH
FRPSOLDQFHZLWKWKHSURWRFRODQG*&3&RPSOLDQFHPD\EHYHULILH GE\RQHRUPRUHRI
WKHIROORZLQJPHWKRGVRQVLWHYLVLWVIUHTXHQWFRPPXQLFDWLRQZ LWKWKH,QYHVWLJDWRUGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 35
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJHDQGRUUHYLHZRI&5)VDQGVRXUFHGRFXPHQWV7KH,QYHVWLJDWRUDJ UHHVWRSHUPLWVXFK
PRQLWRULQJDVZHOODVDXGLWVRUUHYLHZVE\UHJXODWRU\DXWKRULWL HVDQGWKH,5%
5HLPEXUVHPHQW,QGHPQLW\DQG,QVXUDQFH
5HLPEXUVHPHQWLQGHPQLW\DQGLQVXUDQFHVKDOOEHDGGUHVVHGLQD VHSDUDWHDJUHHPHQW
RQWHUPVDJUHHGXSRQE\WKHSDUWLHV
3+$50$&2.,1(7,&$1$/<6,6
$QDO\WLFDO0HWKRGRORJ\
3ODVPDVDPSOHVZLOOEHDQDO\]HGIRUSUHWRPDQLGXVLQJDYDOLGDWH GDVVD\7KHVDPSOHV
IURPDOOHYDOXDEOHVXEMHFWVFRPSOHWLQJDWOHDVWRQHVWXG\SHULR GZLOOEHDQDO\]HG
6DPSOHVIURPVXEMHFWVZKRH[SHULHQFHHPHVLVZLWKLQKRXUVRI GRVLQJZLOOQRWEH
DQDO\]HG
3KDUPDFRNLQHWLFDQG6WDWLVWLFDO$QDO\VHV
3ULPDU\SKDUPDFRNLQHWLFPHDVXUHVLQFOXGH7 PD[&PD[$8&WDQG$8& LQI
6HFRQGDU\SKDUPDFRNLQHWLFPHDVXUHVLQFOXGHWKHUDWLRRI$8& WWR$8& LQI7.HO
&O)DQG9 G)
$OOHYDOXDEOHVXEMHFWVFRPSOHWLQJDWOHDVWRQHWUHDWPHQWSHULRG ZLOOEHLQFOXGHGLQWKH
SKDUPDFRNLQHWLFDQDO\VLV
'HVFULSWLYHVWDWLVWLFVZLOOEHXVHGWRVXPPDUL]HSUHWRPDQLGSOD VPDFRQFHQWUDWLRQVDW
HDFKVDPSOLQJWLPHSRLQWDQGIRUGHULYHGSODVPD3.SDUDPHWHUV DVDSSOLFDEOH
6WDWLVWLFVLQFOXGHVDPSOHVL]HQPHDQ6'SHUFHQWDJHFRHIIL FLHQWRIYDULDWLRQ&9
JHRPHWULFPHDQPHGLDQPLQLPXPDQGPD[LPXP
)RUHDFKSDUWLFLSDQWSUHWRPDQLGSODVPDFRQFHQWUDWLRQWLPHGDWD ZLOOEHJUDSKLFDOO\
SUHVHQWHG6LPLODUO\JUDSKVRIWKHPHDQSODVPDFRQFHQWUDWLRQW LPHSURILOHVDQG
RYHUOD\JUDSKVZLWKFRPELQHGLQGLYLGXDOSODVPDFRQFHQWUDWLRQWL PHSURILOHVZLOOEH
SURGXFHG$GGLWLRQDOO\SKDUPDFRNLQHWLFSDUDPHWHUVPD\EHH[SOR UHGJUDSKLFDOO\
7KHELRDYDLODELOLW\RI[PJGLVSHUVLEOHWDEOHWVUHODWLYHW RWKHPJUHIHUHQFH
WDEOHWZLOOEHGHWHUPLQHGVHSDUDWHO\IRUHDFKSDQHOXVLQJDPL[ HGPRGHOZLWKWKHORJ
WUDQVIRUPHG3.SDUDPHWHU& PD[$8&WDQG$8& LQIDVUHVSRQVHYDULDEOHVHTXHQFH
SHULRGDQGWUHDWPHQWDVIL[HGHIIHFWVDQGSDUWLFLSDQWDVUDQG RPHIIHFW
7KHHIIHFWRIGRVHRQWKHUHODWLYHELRDYDLODELOLW\RIWKHGLVSH UVLEOHWDEOHWZLOOEH
GHWHUPLQHGVHSDUDWHO\IRUHDFKSDQHOXVLQJWKHVDPHPRGHODVDE RYH
7KHHIIHFWRIIRRGRQWKHUHODWLYHELRDYDLODELOLW\RISUHWRPDQL GZLOOEHGHWHUPLQHG
FRPSDULQJDFURVVSDQHOVHDFKIRUPXODWLRQDQGGRVHWDNHQDIWHU HDWLQJEUHDNIDVWYHUVXVGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 36
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJHWKHVDPHIRUPXODWLRQDQGGRVHWDNHQLQIDVWHGFRQGLWLRQVXVLQJ DPL[HGPRGHOZLWKWKH
ORJWUDQVIRUPHG3.SDUDPHWHUDVUHVSRQVHYDULDEOHSDQHOVHTXH QFHSHULRGWUHDWPHQW
DQGSDQHOE\WUHDWPHQWLQWHUDFWLRQDVIL[HGHIIHFWVDQGSDUWLF LSDQWDVUDQGRPHIIHFW
7KH7PD[RISUHWRPDQLGIRUHDFKRIWKHIRUPXODWLRQVZLOOEHGHVFULSWLYHO \FRPSDUHG
2WKHUVWDWLVWLFDOPRGHOVDQGRUSRSXODWLRQSKDUPDFRNLQHWLFPRGH OOLQJPD\DOVREHXVHG
IRUIXUWKHUGDWDLQWHUSUHWDWLRQ
3KDUPDFRNLQHWLFFDOFXODWLRQVZLOOEHSHUIRUPHGXVLQJDSSURSULDW HVRIWZDUH
)$&,/,7,(6
&/,1,&$/75,$/6,7(
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&
1(/RRS6XLWH6DQ$QWRQLR7H[DV7HOHSKRQH)D[

&/,1,&$//$%25$725,(6
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&1(/RRS6XLWH6DQ$QWRQLR7H[DV7HOHSKRQH
)D[

$1$/<7,&$//$%25$725<
$OOLDQFH3KDUPD,QF
3URMHFW0DQDJHU0LFKHOOH%ODFN
&RQWDFWIRU6DPSOH6KLSPHQW$QQD&XFLQRWWD/HH%RXOHYDUG0DOYHUQ3$3KRQH)D[(PDLOVDPSOHV#DOOLDQFHSKDUPDFRFRP:HEZZZDOOLDQFHSKDUPDFRFRP
&/,1,&$/021,725
0LFKHOOH%HKQNH&&5$
6U&OLQLFDO5HVHDUFK$VVRFLDWH&RQVXOWDQW7%$OOLDQFH3KRQHGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 37
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH(PDLOPLFKHOOHEHKQNHFRQVXOWDQW#WEDOOLDQFHRUJ
'$7$0$1$*(0(17$1'67$7,67,&6
:RUOGZLGH&OLQLFDO7ULDOV/WG
VW)ORRU:DWHUIURQW+RXVH%HHVWRQ%XVLQHVV3DUN%HHVWRQ1RWWLQJKDP1*/$8.7HOHSKRQH)D[
'58*6833/,(6
7%$OOLDQFHZLOOVXSSO\VXIILFLHQWTXDQWLWLHVRIDOOVWXG\GUXJ IRUPXODWLRQVWRDOORZ
FRPSOHWLRQRIWKLVVWXG\
6WXG\GUXJIRUPXODWLRQVZLOOEHVKLSSHGWR:RUOGZLGH&OLQLFDO7 ULDOV(DUO\3KDVH
6HUYLFHV//&SXUVXDQWWRVLWHVWDQGDUGRSHUDWLQJSURFHGXUHV8 SRQUHFHLSWRIWKHVWXG\
GUXJSURGXFWVWKHVXSSOLHVZLOOEHLQYHQWRULHGDQGVWRUHGLQD QHQYLURQPHQWDOO\
FRQWUROOHGDQGVHFXUHOLPLWHGDFFHVVDUHD7KHORWQXPEHUVRI WKHGUXJVDORQJZLWKWKH
H[SLUDWLRQGDWHVZKHUHDYDLODEOHZLOOEHUHFRUGHGDQGFRSLHV RIWKH&HUWLILFDWHRI
$QDO\VLVZKHUHDYDLODEOHZLOOEHPDLQWDLQHGRQILOH5HFRUGV ZLOOEHPDLQWDLQHGRI
WKHUHFHLSWDQGGLVSHQVDWLRQRIWKHGUXJVVXSSOLHG
6XIILFLHQWTXDQWLWLHVRIVWXG\GUXJZLOOEHVXSSOLHGWRDOORZI RUUHWHQWLRQVDPSOHV
5HWHQWLRQVDPSOHVZLOOEHVWRUHGDWWKHFOLQLFDOVLWHSXUVXDQW WRWKHVLWH623V7KHVLWH
ZLOOEHUHVSRQVLEOHIRUUDQGRPO\VHOHFWLQJGRVHVWREHDGPLQLVW HUHGDQGGRVHVWREH
UHWDLQHG$WWKHFRQFOXVLRQRIWKHVWXG\ DQ\XQXVHGVWXG\GUXJQRWLQFOXGLQJUHWHQWLRQ
VDPSOHVZLOOEHUHWXUQHGWRWKHVSRQVRURUGHVWUR\HGE\WKHVL WHSXUVXDQWWRZULWWHQ
DXWKRUL]DWLRQE\WKHVSRQVRUDQGDSSOLFDEOHIHGHUDODQGVWDWHU HJXODWLRQV
$'0,1,675$7,9(,668(6
7KH,QYHVWLJDWRULVUHIHUUHGWRWKH,QYHVWLJDWRU%URFKXUHIRUS UHWRPDQLG3$

LQIRUPDWLRQSURYLGHGGXULQJWKHVWXG\LQLWLDWLRQYLVLWDQG,&+ *XLGHOLQHVIRU*RRG
&OLQLFDO3UDFWLFHIRULQIRUPDWLRQUHJDUGLQJWKHVWXG\GUXJGHW DLOVRUJHQHUDO
FRQVLGHUDWLRQVWREHIROORZHGGXULQJWKHFRXUVHRIWKLVVWXG\Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 38
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH(9(1766&+('8/(
7DEOH 6FKHGXOHRI$VVHVVPHQWVDQG3URFHGXUHV
 6&5 &RQILQHPHQW7R'D\ 
678'<3(5,2' 
WR6HVVLRQ %UHDN 6HVVLRQ %UHDN 6HVVLRQ %UHDN 6HVVLRQ
678'<'$<  RUHDUO\
ZLWKGUDZDO
:ULWWHQLQIRUPHGFRQVHQW
DQGPHGLFDOKLVWRU\ ;
8SGDWHGPHGLFDOKLVWRU\ ;
+HLJKW ;
:HLJKW ;;
3K\VLFDOH[DPLQDWLRQD ;;;
9LWDOVLJQVEORRGSUHVVXUHSXOVH
WHPSHUDWXUHUHVSLUDWLRQUDWHDQG
SXOVHR[LPHWU\E
;;;;;;;;;;;;;;;;;;;;;;;;;;
6LQJOHOHDG(&*F ;;;;;;;
+,9KHSDWLWLV%VXUIDFHDQWLJHQ
DQGKHSDWLWLV&;
&OLQLFDOODERUDWRU\WHVWV
KHPDWRORJ\FKHPLVWU\DQG
XULQDO\VLVG
;;;;;;
;
8ULQHGUXJFRWLQLQHDOFRKROWHVW;;;
6HUXPSUHJQDQF\WHVWIHPDOHV ;;
8ULQHSUHJQDQF\WHVWIHPDOHV ;
)6+SRVWPHQRSDXVDOZRPHQ ;
&RQFRPLWDQWPHGLFDWLRQV ;;;;;;;;;;;;;;;;;;;;;;;;;;
$GYHUVHHYHQWVH ;;;;;;;;;;;;;;;;;;;;;;;;;;
'RVLQJI;;;;
3KDUPDFRNLQHWLFEORRGFROOHFWLRQJ;;;;;;;;;;;;;;;;;;;;Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 39
3URWRFRO3D&/9
7%$OOLDQFH &21),'(17,$/ 'HF
3DJHD3K\VLFDO([DPLQDWLRQ)XOOSK\VLFDOH[DPLQDWLRQDWVFUHHQLQJDQG DEEUHYLDWHGSK\VLFDO
H[DPLQDWLRQDWFKHFNLQ+HLJKWZLOORQO\EHFROOHFWHGDWVFUHHQL QJ
E9LWDO6LJQV0HDVXUHGDWFKHFNLQDQGZKLOHSDUWLFLSDQWVDUHFR QILQHGWRWKHFOLQLFRQFHSHU
GD\RUDVRWKHUZLVHQHHGHG>GHWHUPLQHGE\WKH,QYHVWLJDWRU@9L WDOVLJQVZLOOEHPHDVXUHG
ZLWKLQPLQXWHVSULRUWRGRVLQJDQGZLWKLQPLQXWHVRIWKH UHPDLQLQJGHILQHG
WLPHSRLQWV %RWKEORRGSUHVVXUHDQGKHDUWUDWHSXOVHVKRXOGEH FDSWXUHGVLPXOWDQHRXVO\
%ORRGSUHVVXUHDQGKHDUWUDWHVKRXOGEHPHDVXUHGDIWHUSDUWLFLS DQWVDUHLQDVHDWHGSRVLWLRQ
IRUDWOHDVWPLQXWHVDQGWKHQDJDLQDIWHUVWDQGLQJIRUPLQXW HH[FHSWZKHQWKH\DUHVXSLQH
RUVHPLUHFOLQHGEHFDXVHRIVWXG\SURFHGXUHVDQGRUDGYHUVHHYH QWVRUDVGHHPHGQHFHVVDU\
E\WKH,QYHVWLJDWRU
F(&*OHDGVDIHW\(&*VZLOOEHSULQWHGDQGUHYLHZHGRQVLWHE\ WKH3ULQFLSDO,QYHVWLJDWRU
RUGHVLJQHH6LQJOH(&*VZLOOEHREWDLQHGDWVFUHHQLQJDQGRQ6W XG\'D\VDQG
DQGPXVWEHSHUIRUPHGZLWKLQKRXUVSULRUWRGRVLQJDQGFRPSOHWH GPLQXWHVSULRUWR
SUHGRVHEORRGGUDZ
G/DERUDWRU\6DIHW\$VVHVVPHQWV+DHPDWRORJ\KDHPRJORELQKDHPDW RFULWWRWDODQG
GLIIHUHQWLDOOHXNRF\WHFRXQWUHGEORRGFHOOFRXQWDQGSODWHOHWF RXQW6HUXPFKHPLVWU\
DOEXPLQEORRGXUHDQLWURJHQFUHDWLQLQHWRWDOELOLUXELQDOND OLQHSKRVSKDWDVHDVSDUWDWH
WUDQVDPLQDVHDODQLQHWUDQVDPLQDVHVRGLXPSRWDVVLXPFKORULGH ODFWDWHGHK\GURJHQDVH
FDOFLXPXULFDFLGJOXFRVHJDPPDJOXWDP\OWUDQVIHUDVHDQGPDJQ HVLXP8ULQDO\VLVS+
VSHFLILFJUDYLW\SURWHLQJOXFRVHNHWRQHVELOLUXELQEORRGQ LWULWHOHXNRF\WHHVWHUDVHDQG
XURELOLQRJHQ,ISURWHLQRFFXOWEORRGQLWULWHRUOHXNRF\WHHVW HUDVHYDOXHVDUHRXWRIUDQJHD
PLFURVFRSLFH[DPLQDWLRQZLOOEHSHUIRUPHG
H$GYHUVH(YHQWV$(V3DUWLFLSDQWVZLOOEHPRQLWRUHGIRU$(VIURP WKHWLPHRIVLJQLQJWKH
LQIRUPHGFRQVHQWGRFXPHQWDQGWKURXJKRXWWKHVWXG\YLDVDIHW\DV VHVVPHQWVREVHUYDWLRQ
DQGSDUWLFLSDQWUHSRUWLQJ$VSHFLILFLQTXLU\UHJDUGLQJDGYHUVH HYHQWVZLOOEHFRQGXFWHG
SULRUWRGRVLQJDQGDWWLPHSRLQWVGHWHUPLQHGE\WKH,QYHVWLJDWR USRVWGRVHDQGXSRQUHWXUQWR
FOLQLFIRUVXEVHTXHQWYLVLWV
I,QYHVWLJDWLRQDO0HGLFLQDO3URGXFW,03$GPLQLVWUDWLRQ6HH )LJXUH
J3KDUPDFRNLQHWLF3.6DPSOLQJ%ORRGVDPSOHVIRUDQDO\VLVRISU HWRPDQLGFRQFHQWUDWLRQV
ZLOOEHGUDZQMXVWEHIRUHGUXJLQWDNHSUHGRVHDQGDW 
DQGKRXUVSRVWGRVHVDPSOHVSHULQWDNH'XSOLFDWHVD PSOHVZLOOEHFROOHFWHGIRU
DOOSODVPDSKDUPDFRNLQHWLFVDPSOHVGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 40
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH5()(5(1&(6
,QYHVWLJDWRU¶V%URFKXUHIRU3UHWRPDQLG3$9HUVLRQ 2FWREHU
*OREDO$OOLDQFHIRU7%'UXJ'HYHORSPHQW
:+2*OREDO7%5HSRUWD
:+2*OREDO7%5HSRUW
/XQD-$&$WXEHUFXORVLVJXLGHIRUVSHFLDOLVWSK\VLFLDQV,QWH UQDWLRQDO8QLRQ
DJDLQVW7XEHUFXORVLVDQG/XQJ'LVHDVH
&HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQ)DFW6KHHW 7UHQGVLQ
7XEHUFXORVLV$WODQWD*$86'HSDUWPHQWRI+HDOWKDQG +XPDQ6HUYLFHV
&'&6HSWHPEHU
³&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&7&$(YHUVLRQ ´86
'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV1RYHPEHU
³*XLGDQFH)RU,QGXVWU\6WDWLVWLFDO$SSURDFKHVWR(VWDEOLVKLQJ %LRHTXLYDOHQFH´
86'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV)RRGDQG'UXJ$GPL QLVWUDWLRQ
&HQWHUIRU'UXJ(YDOXDWLRQDQG5HVHDUFK&'(5-DQXDU\
³*XLGDQFH)RU,QGXVWU\%LRDYDLODELOLW\DQG%LRHTXLYDOHQFH6WXG LHVIRU2UDOO\
$GPLQLVWHUHG'UXJ3URGXFWV*HQHUDO&RQVLGHUDWLRQV´86'HSDUWP HQWRI+HDOWK
DQG+XPDQ6HUYLFHV)RRGDQG'UXJ$GPLQLVWUDWLRQ&HQWHUIRU'UXJ (YDOXDWLRQ
DQG5HVHDUFK&'(50DUFKGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 41
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH$33(1',; 3+$50$&2.,1(7,&6$03/(&2//(&7,21352&(66,1*$1'
6+,30(17,16758&7,216
$&ROOHFWLRQDQG3URFHVVLQJ
$PRUHGHWDLOHGGHVFULSWLRQRISODVPDVDPSOHSUHSDUDWLRQUHTXLU HPHQWVPD\EHSURYLGHGE\WKH
DQDO\WLFDOODERUDWRU\,IVXFKDGHVFULSWLRQLVSURYLGHGWKHP HWKRGRIVDPSOHSUHSDUDWLRQ
SURYLGHGE\WKHODERUDWRU\VKDOOVXSHUVHGHWKRVHSURYLGHGLQWK LVSURWRFRODQGDSSURSULDWH
GRFXPHQWDWLRQVKDOOEHSODFHGLQWKH,QYHVWLJDWRU6LWH)LOH,6 )
3URFHVVLQJ,QVWUXFWLRQV
%ORRGVDPSOHVZLOOEHFROOHFWHGLQWRP/9DFXWDLQHUWXEHV FRQWDLQLQJ. ('7$
7KHWLPHDQGGDWHRIFROOHFWLRQIRUHDFKVDPSOHZLOOEHUHFRUGH G
'XULQJHDFKWUHDWPHQWSHULRGVDPSOHVZLOOEHFROOHFWHGDWKR XUSUHGRVHZLWKLQ
PLQXWHVEHIRUHWKHGRVHRIVWXG\GUXJDQGDW 
DQGKRXUVSRVWGRVH 
1RWH3UHGRVHEORRGVDPSOHVREWDLQHGI URPEDFNXSVXEMHFWVZKRDUHUDQGRPL]HG
LQWRWKHVWXG\PD\H[FHHGWKHSUHGRVHFROOHFWLRQZLQGRZ
%ORRGVDPSOHVZLOOEHFHQWULIXJHGDWDSSUR[LPDWHO\USPIRU PLQXWHVDW
DSSUR[LPDWHO\GHJUHHV&HQWLJUDGH
7KHUHVXOWLQJSODVPDVDPSOHVZLOOEHKDUYHVWHGDQGWUDQVIHUUHG LQDSSUR[LPDWHO\
HTXDODOLTXRWVLQWRWZRDSSURSULDWHO\ODEHOHGSRO\SURS\OHQHVFU HZFDSWXEHV
6DPSOHVZLOOEHSODFHGLQDQXSULJKWSRVLWLRQLQDIUHH]HUDWD SSUR[LPDWHO\
GHJUHHV&HQWLJUDGHZLWKLQPLQXWHVRIFROOHFWLRQ
6DPSOHVZLOOUHPDLQIUR]HQXQWLODVVD\HG 

6DPSOH&ROOHFWLRQ6XPPDU\
1XPEHU
RI
VXEMHFWV1XPEHURI
WLPHSRLQWV
SHUSHULRG1XPEHU
RISHULRGV6DPSOHW\SH 7XEHW\SH1XPEHURIWXEHVSHU
WLPHSRLQW
  &ROOHFWLRQP/. ('7$
9DFXWDLQHU
$OLTXRWX/3RO\SURS\OHQH
VFUHZ&DSGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 42
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH%/DEHOLQJRIDOLTXRWWXEHV
/DEHOVZLOOFRQWDLQDWOHDVWWKHIROORZLQJLQIRUPDWLRQD6WXG\QXPEHU
E6XEMHFWLGHQWLILFDWLRQ
F3HULRGRUGRVLQJSKDVHVDPSOLQJWLPHUHODWLYHWRGRVLQJ
G$OLTXRWOHWWHUDRUE
&6KLSPHQW
7KHVDPSOHVZLOOEHWUDQVIHUUHGWRWKHDQDO\WLFDOODERUDWRU\DI WHUFRPSOHWLRQRIWKH
VWXG\RUDWPXWXDOO\DJUHHGXSRQWLPHSRLQWVGXULQJWKHFOLQLFD OFRQGXFWRIWKHVWXG\
7KHVHFRQGVHWRIVDPSOHVZLOOEHVKLSSHGDIWHUWKHELRDQDO\WLF DOODERUDWRU\FRQILUPV
UHFHLSWRIWKHILUVWVHWRIVDPSOHV
6DPSOHVZLOOEHSDFNDJHGLQWRFU\RER[HVDQGVRUWHGE\VXEMHFW 
%HIRUHVKLSPHQWWKHVDPSOHVZLOOEHDSSURSULDWHO\SDFNHGLQD FRROHUFRQWDLQLQJGU\
LFH6XIILFLHQWGU\LFHZLOOEHDGGHGWRHQVXUHWKDWWKHVDPSOH VZLOOUHPDLQIUR]HQIRUDW
OHDVWKRXUV
$QHOHFWURQLFPDQLIHVWZLOOEHSURYLGHGLQDGYDQFH7KHVKLSPHQ WZLOOEHDFFRPSDQLHG
E\GRFXPHQWDWLRQFRQWDLQLQJWKHIROORZLQJLQIRUPDWLRQQDPHRI WKHVWXG\GUXJ
SURGXFWSURWRFROQXPEHUQXPEHURIVXEMHFWVDQGQXPEHURIVDP SOHVLQFOXGHGLQWKH
VKLSPHQW([SHFWHGVDPSOHVWKDWDUHQRWSUHVHQWZLOOEHLGHQWLI LHG
$OOIUR]HQSKDUPDFRNLQHWLFVDPSOHVZLOOEHWUDQVIHUUHGZLWKDFF RPSDQ\LQJ
GRFXPHQWDWLRQWR
$OOLDQFH3KDUPD
/HH%RXOHYDUG0DOYHUQ3HQQV\OYDQLD7HOHSKRQH&RQWDFWQDPH0LFKHOOH%ODFN(PDLOVDPSOHV#DOOLDQFHSKDUPDFRFRP
  PEODFN#DOOLDQFHSKDUPDFRFRPGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 43
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH$33(1',;',9,6,212)0,&52%,2/2*<$1',1)(&7,286',6($6(
72;,&,7<7$%/(
'LYLVLRQRI0LFURELRORJ\DQG,QIHFWLRXV'LVHDVH'0,'7R[LFLW\ 7DEOH
6RXUFH861DWLRQDO,QVWLWXWHRI$OOHUJ\DQG,QIHFWLRXV'LVH DVHV'0,'1RYHPEHU
'UDIW
$%%5(9,$7,216 $EEUHYLDWLRQVXWLOL]HGLQWKH7DEOH
8/1 8SSHU/LPLWRI1RUPDO //1 /RZHU/LPLWRI1RUPDO
5[ 7KHUDS\ 5HT 5HTXLUHG
0RG 0RGHUDWH ,9 ,QWUDYHQRXV
$'/ $FWLYLWLHVRI'DLO\/LYLQJ 'HF 'HFUHDVHG

(67,0$7,1*6(9(5,7<*5$'(
)RUDEQRUPDOLWLHV127IRXQGHOVHZKHUHLQWKH7R[LFLW\7DEOHVXV HWKHVFDOHEHORZWRHVWLPDWH
JUDGHRIVHYHULW\
*UDGH 6HYHULW\5DWLQJ 'HILQLWLRQ
*5$'(  0LOG7UDQVLHQWRUPLOGGLVFRPIRUWKRXUVQRPHGLFDO
LQWHUYHQWLRQWKHUDS\UHTXLUHG
*5$'( 0RGHUDWH0LOGWRPRGHUDWHOLPLWDWLRQLQDFWLYLW\VRPHDVVLVWDQFHPD\E H
QHHGHGQRRUPLQLPDOPHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHG
*5$'(  6HYHUH0DUNHGOLPLWDWLRQLQDFWLYLW\VRPHDVVLVWDQFHXVXDOO\UHTXLUHG 
PHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHGKRVSLWDOL]DWLRQVSRVVLEO H
*5$'( 3RWHQWLDOO\/LIH
WKUHDWHQLQJ([WUHPHOLPLWDWLRQLQDFWLYLW\VLJQLILFDQWDVVLVWDQFHUHTXLUHG 
VLJQLILFDQWPHGLFDOLQ WHUYHQWLRQWKHUDS\UHTXLUH GKRVSLWDOL]DWLRQRU
KRVSLFHFDUHSUREDEOH

6(5,28625/,)(7+5($7(1,1*$(V
$1<FOLQLFDOHYHQWGHHPHGE\WKHFOLQLFLDQWREHVHULRXVRUOLI HWKUHDWHQLQJVKRXOGEH
FRQVLGHUHGDJUDGHHYHQW&OLQLFDOHYHQWVFRQVLGHUHGWREHVH ULRXVRUOLIHWKUHDWHQLQJLQFOXGH
EXWDUHQRWOLPLWHGWRVHL]XUHVFRPDWHWDQ\GLDEHWLFNHWRDF LGRVLVGLVVHPLQDWHGLQWUDYDVFXODU
FRDJXODWLRQGLIIXVHSHWHFKLDHSDUDO\VLVDFXWHSV\FKRVLVVHY HUHGHSUHVVLRQ
&200(1765(*$5',1*7+(86(2)7+(6(7$%/(6
x6WDQGDUGL]HGDQGFRPPRQO\XVHGWR[LFLW\WDEOHV'LYLVLRQRI$,' 61&,¶V&RPPRQ
7R[LFLW\&ULWHULD&7&DQG:RUOG+HDOWK2UJDQL]DWLRQ:+2K DYHEHHQDGDSWHGIRUXVH
E\WKH'LYLVLRQRI0LFURELRORJ\DQG,QIHFWLRXV'LVHDVHV'0,' DQGPRGLILHGWREHWWHU
PHHWWKHQHHGVRI3DWLHQWVLQ'0,'WULDOV
x)RUSDUDPHWHUVQRWLQFOXGHGLQWKHIROORZLQJ7R[LFLW\7DEOHVV LWHVVKRXOGUHIHUWRWKH³*XLGH
)RU(VWLPDWLQJ6HYHULW\*UDGH´ORFDWHGDERYHGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 44
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJHx&ULWHULDDUHJHQHUDOO\JURXSHGE\ERG\V\VWHP
x6RPHSURWRFROVPD\KDYHDGGLWLRQDOSURWRFROVSHFLILFJUDGLQJFU LWHULDZKLFKZLOOVXSHUVHGH
WKHXVHRIWKHVHWDEOHVIRUVSHFLILHGFULWHULD
+(0$72/2*< 
 *UDGH *UDGH *UDGH *UDGH
+HPRJORELQ  JPG/ JPG/ JPG/ JPG/ 
$EVROXWH1HXWURSKLO
&RXQWPPPPPP PP
3ODWHOHWV PPPPPPPP
:%&V
PP
PPPP!RU
PP
3RO\PRUSKRQXFOHDU
/HXFRF\WHV%DQG&HOOV ! ± ! 
$EQRUPDO)LEULQRJHQ/RZ
PJG/
+LJK
PJG//RZ
PJG/ 
+LJK
!PJG/ /RZ
PJG/

)LEULQRJHQ
DVVRFLDWHGZLWK
JURVVEOHHGL QJRU
ZLWKGLVVHPLQDWHG
FRDJXODWLRQ
)LEULQ6SOLW3URGXFW  PFJ PO PFJPO PFJ PO !PFJPO 
3URWKURPELQ7LPH37 [8/1 [8 /1 [8/1 ![8/1
$FWLYDWHG3DUWLDO
7KURPERSODVWLQ$337 [8/1 [8/1 [8/1  ![8/1
0HWKHPRJORELQ      !

&+(0,675,(6 
 *UDGH *UDGH *UDGH *UDGH
+\SRQDWUHPLD  P(T/ P(T/ P(T/P(T/RUDEQRUPDO
VRGLXPZLWKPHQWDOVWDWXV
FKDQJHVRUVHL]XUHV
+\SHUQDWUHPLD P(T/ P(T/ P (T/!P(T/RUDEQRUPDO
VRGLXPZLWKPHQWDOVWDWXV
FKDQJHVRUVHL]XUHV
+\SRNDOHPLD  P(T/ P(T/P(T/RU
LQWHQVLYH
UHSODFHPHQW
WKHUDS\RU
KRVSLWDOL]DWLRQ
UHTXLUHGP(T/ RUDEQRUPDO
SRWDVVLXP ZLWKSDUHVLVLOHXV
RUOLIHWKUHDWHQLQJDUU K\WKPLDGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 45
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH&+(0,675,(6 
 *UDGH *UDGH *UDGH *UDGH
+\SHUNDOHPLD  P(T/ P(T/ P(TO!P(T/RUDEQRUPDO
SRWDVVLXP ZLWKOLIH
WKUHDWHQLQJDUUK\WKPLD
+\SRJO\FHPLD  PJG/ PJG/ PJG/ PJG/RUDEQRUPDO
JOXFRVHZLWKPHQWDOVWDWXV
FKDQJHVRUFRPD
+\SHUJO\FHPLD
QRQIDVWLQJDQGQR
SULRUGLDEHWHVPJG/ PJG/ PJG/!PJG/ RUDEQRUPDO
JOXFRVHZLWKNHWRDFLGRVLVRU
VHL]XUHV
+\SRFDOFHPLD
FRUUHFWHGIRU
DOEXPLQPJ G/PJG/ PJ G/PJG/RUDEQRUPDO
FDOFLXPZLWKOLIHWKUHDWHQLQJ
DUUK\WKPLDRUWHWDQ\
+\SHUFDOFHPLD 
FRUUHFWIRUDOEXPLQPJG/
PJG/PJG/!PJG/RU DEQRUPDO
FDOFLXPZLWKOLIHWKUHDWHQ LQJ
DUUK\WKPLD
+\SRPDJQHVHPLD P(T/ P(T/ P(T/P(T/RU DEQRUPDO
PDJQHVLXP ZLWKOLIH
WKUHDWHQLQJDUUK\WKPLD
+\SRSKRVSKDWHPLD PJG/PJG/
RUUHSODFHPHQW
5[UHTXLUHGPJG/
LQWHQVLYHWKHUDS\RU
KRVSLWDOL]DWLRQ
UHTXLUHGPJG/RUDEQRUPDO
SKRVSKDWH ZLWKOLIH
WKUHDWHQLQJDUUK\WKPLD 
+\SHUELOLUXELQHPLDZKHQDFFRPSDQLHGE\DQ\LQFUHDVHLQ
RWKHUOLYHUIXQFWLRQ
WHVW [8/1[
8/1±[8/1 ![8/1
+\SHUELOLUXELQHPLD
ZKHQRWKHUOLYHU
IXQFWLRQDUHLQWKH
QRUPDOUDQJH [8/1 [8/1 ±[8/1 ![8/1
%81 [8/1 [8/1 [8/1  ![8/1
+\SHUXULFHPLD XULF
DFLG±PJG/±
PJG/±PJG/ !PJG/
&UHDWLQLQH  [8/1 [8/1 [8/1 ![8/1RUGLDO\VLV
UHTXLUHG

(1=<0(6 
 *UDGH *UDGH *UDGH *UDGH
$676*27  [8/1 ±[8/1 ±[8/1 ![8/1
$/76*37  [8/1 ±[8/1 ±[8/1 ![8/1Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 46
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH(1=<0(6 
 *UDGH *UDGH *UDGH *UDGH
**7 [ 8/1 ±[8/1 ±[8/1 ![8/1
$ONDOLQH3KRVSKDWDVH [8/1 ±[8/1 ±[8/1 ![8/1
$P\ODVH  [8/1 [8/1 [ 8/1 ![8/1 
/LSDVH [8/1 [8/1 [8/1 ![8/1 

85,1$/<6,6 
 *UDGH *UDGH *UDGH *UDGH
3URWHLQXU LDRUPJ 
JPORVVGD\ RU JP
ORVVGD\RUJP
ORVVGD\QHSKURWLFV\QGURPH
RU!JP
ORVVGD\
+HPDWXULD
PLFURVFRSLFRQO\
UEFKSIJURVVQRFORWV!
UEFKSIJURVVZLWKRU
ZLWKRXWFORWV25
UHGEORRGFHOOFDVWVREVWUXFWLYH RU
UHTXLUHGWUDQVIXVLRQ

$VVHVVPHQWGRHVQRWDSSO\LIDVXEMHFWLVRQPHQVHV
&$5',29$6&8/$5
 *UDGH *UDGH *UDGH *UDGH
&DUGLDF5K\WKP  DV\PSWRPDWLF
WUDQVLHQWVLJQVQR5
[UHTXLUHGUHFXUUHQWSHUVLVWHQW
V\PSWRPDWLF5[UHTXLUHG
XQVWDEOH
G\VU\WKPLD 
KRVSLWDOL]DWLRQDQG
WUHDWPHQWUHTXLUHG
+\SHUWHQVLRQ WUDQVLHQWLQFUHDVH
!PP+JQRWUHDW
PHQWUHFXUUHQWFKURQLF
LQFUHDVH!
PP+J
WUHDWPHQWUHTXLUHGDFXWHWUHDWPHQW
UHTXLUHGRXWSDWLHQW
WUHDWPHQWRU
KRVSLWDOL]DWLRQ
SRVVLEOHHQGRUJDQGDPDJH
RUKRVSLWDOL]DWLRQUHTXLUHG

+\SRWHQVLRQ WUDQVLHQW
RUWKRVWDWLFK\SRWHQVLRQZLWKKHDUW
UDWH
LQFUHDVHGE\
EHDWPLQRU 
GHFUHDVHGE\
PP+JV\VWROLF%31RWUHDWPHQWUHTXLUHG
V\PSWRPVGXHWR
RUWKRVWDWLFK\SRWHQVLRQRU%3GHFUHDVHGE\PP+JV\VWROLFFRUUHFWDEOHZLWKRUDO
IOXLGWUHDWPHQW
UHTXLUHV,9IOXLGVQR
KRVSLWDOL]DWLRQUHTXLU
HGPHDQDUWHULDO
SUHVVXUHPP+
JRUHQGRUJDQ
GDPDJHRUVKRFNUHTXLUHVKRVSLWDOL]DWLRQDQG
YD
VRSUHVVRU
WUHDWPHQWGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 47
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH&$5',29$6&8/$5
 *UDGH *UDGH *UDGH *UDGH
3HULFDUGLWLV PLQLPDOHIIXVLRQ PLOGPRGHUDWH
DV\PSWRPDWLF 
HIIXVLRQQR
WUHDWPHQWV\PSWRPDWLF
HIIXVLRQSDLQ(.*FK
DQJHVWDPSRQDGH
SHULFDUGLRFHQWHVLVRUVXUJHU\UHTXLUHG
+HPRUUKDJH%ORRG
/RVVPLFURVFRSLFRFFXOW PLOGQRWUDQVIXVLRQ JURVVEORRGORVV
XQLWVWUDQV IXVHGPDVVLYHEORRG
ORVV!XQLWVWUDQVIXVHG
)RUSURWRFRO7%,&/GHILQHGDVLQFUHDVHIURPEDVHOL QHLQSUHGRVHYLWDOVLJQV

5(63,5$725< 
 *UDGH *UDGH *UDGH *UDGH
&RXJK7UDQVLHQW QR
WUHDWPHQWSHUVLVWHQWFRXJK 
WUHDWPHQWUHVSRQVLYH3DUR[\VPDOFRXJK
XQFRQWUROOHGZLWK
WUHDWPHQW
%URQFKRVSDVP
$FXWHWUDQVLHQWQR
WUHDWPHQW
)(9 RISHDN
IORZUHTXLUHVWUHDWPHQW
QRUPDOL]HVZLW K
EURQFKRGLODWRU)(9 
 RISHDN
IORZQRQRUPDOL]DWLRQZLWK
EURQFKRGLODWRU)(9 
RISHDN
IORZRUUHWUDFWL RQV
SUHVHQWF\DQRVLV)(9 
RISHDNIORZ
RULQWXEDWLR Q
QHFHVVDU\
'\VSQHD  G\VSQHDRQH[HU WLRQG\VSQHDZLWKQRUPDO
DFWLYLW\G\VSQHDDWUHVWG\VSQHDUHTXLULQJ
2[\JHQWKHUDS\

*$6752,17(67,1$/
 *UDGH *UDGH *UDGH *UDGH
1DXVHD PLOGRUWUDQVLHQWPDLQWDLQVUHDVRQDEOHLQWDNH PRGHUDWHGLVFRPIRUWLQWDNHG
HFUHDVHG
VLJQLILFDQWO\VRPHDFWLYLW\OLPLWHGQRVLJQLILFDQWLQWDNHU
HTXLUHV,9
IOXLGVKRVSLWDOL]DWLRQUHTXLUHG

9RPLWLQJ HSLVRGHLQKRXUV
HSLVRGHVLQKRXUV
!HSLVRGHVLQKRXUVRUQHHGLQJ,9IOXLGV
SK\VLRORJLF
FRQVHTXHQFHV
UHTXLULQJ
KRVSLWDOL]DWLRQRUUHTXLULQJSDUHQWHUDOQXWULWLRQ
&RQVWLSDWLRQ UHTXLULQJVWRROVRIWHQHURUGLHWDU\
PRGLILFDW
LRQUHTXLULQJOD[DWLYHV REVWLSDWLRQUHTXLULQJPDQXDO
HYDFXDWLRQRU
HQHPDREVWUXFWLRQRU WR[LF
PHJDFRORQ 
'LDUUKHD PLOGRUWUDQVLHQWORRVHVWRROVGD\RUPLOGGLDUUKHD PRGHUDWHRUSHUVLVWHQW
ORRVH
VWRROVGD\RU!ORRVHVWRROVGD\RUEORRG\GLDUUKHDRURUWKRVWDWLF K\SRWHQVLYHVKRFN 
RUSK\VLRORJL F
FRQVHTXHQFHVGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 48
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH*$6752,17(67,1$/
 *UDGH *UDGH *UDGH *UDGH
ODVWZHHN GLDUUKHDODVWLQJ!
ZHHNK\SRWHQVLRQRU
HOHFWURO\WHLPEDODQFHRU!/,9IOXLGVUHTXLUHGUHTXLULQJ
KRVSLWDOL]D WLRQ
2UDO
'LVFRPIRUW'\VSKDJLDPLOGGLVFRPIRUWQR
GLIILFXOW\VZDOORZLQJVRPHOLPLWVRQ
HDWLQJGULQNLQJHDWLQJWDONLQJYHU\
OLPLWHGXQDEOHWRVZDOORZVROLGIRRGVXQDEOHWRGULQN
IOXLGVUHTXLUHV,9IOXLGV

1(852/2*,&$/
 *UDGH *UDGH *UDGH *UDGH
1HXUR&HUHEHOODU VOLJKW
LQFRRUGLQDWLRQ
G\VGLDGRFKRNLQHVLVLQWHQWLRQWUHPRU
G\VPHWULDVOXUUHG
VSHHFKQ\VWDJPXVORFRPRWRUDWD[LD LQFDSDFLWDWHG
3V\FKLDWULF PLOGDQ[LHW\RU
GHSUHVVLRQ PRGHUDWHDQ[LHW\RU
GHSUHVVLRQWKHUDS\UHTXLUHGFKDQJHLQQRUPD
OURXWLQHVHYHUHPRRG
FKDQJHVUHTX LULQJ
WKHUDS\RUVXLFLGDOLGHDWL
RQRU
DJJUHVVLYHLGHDWLRQDFXWHSV\FKRVLV
UHTXLULQJ
KRVSLWDOL]DWLRQRU
VXLFLGDOJHVWXUHDWWHPSWRU
KDOOXFLQDWLRQV
0XVFOH6WUHQJWK 6XEMHFWLYH 
ZHDNQHVVQR
REMHFWLYH
V\PSWRPVVLJQVPLOGREMHFWLYH
VLJQVV\PSWRPVQRGHFUH
DVHLQIXQFWLRQREMHFWLYHZHDNQHVV
IXQFWLRQOLPLWHG SDUDO\VLV
3DUHVWKHVLDEXUQLQJ
WLQJOLQJHWF PLOGGLVFRPIRUWQR
WUHDWPHQWUHTXLUHGPRGHUDWH
GLVFRPIRUWQRQ 
QDUFRWLFDQDOJHVLD
UHTXLUHGVHYHUHGLVFRPIRUW
RUQDUFRWLF
DQDOJHVLDUHTXLUHG
ZLWKV\PSWRP DWLF
LPSURYHPHQWLQFDSDFLWDWLQJRU
QRWUHVSRQVLYH WR
QDUFRWLFDQDOJHVLD
1HXURVHQVRU\ PLOGLPSDLUPHQWLQ
VHQVDWLRQGHFUHDVHGVHQVDWLRQHJYLEUDWRU\SLQSULFNKRWFROGLQJUHDWWRHVLQIRFDODUHDRUV
\PPHWULFDO
GLVWULEXWLRQRU
FKDQJHLQWDVWH
VPHOOYLVLRQDQGRU
KHDULQJPRGHUDWH
LPSDLUPHQWPRGG
HFUHDVHG
VHQVDWLRQHJ
YLEUDWRU\SLQSULFNKRWFROGWRDQNOHVDQGRUMRLQWSRVLWLRQRUPLOGLPSDLUPHQWWKDWLVQRWV\PPHWULFDO
VHYHUHLPSDLUPHQW
GHFUHDVHGRUORVVR
IVHQVDWLRQWR
NQHHVRUZULVWVRU
ORVVRIVHQVDWLRQRI
DWOHDVWPRG 
GHJUHHLQPXOWLSOH
GLIIHUHQWERG\
DUHDVLHXSSHU
DQGORZHUH[WUHPLWLHV
VHQVRU\ORVV
LQYROYHVOLPEVDQGWUXQNSDUDO\VLVRU 
VHL]XUHV


Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 49
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH086&8/26 .(/(7$/
 *UDGH *UDGH *UDGH *UDGH
$UWKUDOJLDMRLQWSDLQ PLOGSDLQQRW
LQWHUIHULQJZLWKIXQFWL
RQPRGHUDWHSDLQ
DQDOJHVLFVDQGRUSDLQLQWHUIHULQJZLWK
IXQFWLRQEXWQRWZLWK
DFWLYLWLHVRI
GDLO\
OLYLQJVHYHUHSDLQSDLQ
DQGRUDQDOJHVLFVLQWHUIHUL
QJZLWK
DFWLYLWLHVRI GDLO\
OLYLQJGLVDEOLQJSDLQ
$UWKULWLV PLOGSDLQZLWK
LQIODPPDWLRQHU\WKHPDRUMRLQWVZHOOLQJ
±EXWQRW
LQWHUIHULQJZLWK
IXQFWLRQPRGHUDWHSDLQZLWK
LQIODPPDWLRQHU\WKHPDRUMRLQWVZHOOLQJ
±LQWHUIHULQJ
ZLWKIXQFWLRQEXWQRW
ZLWKDFWLYLWLHVRI
GDLO\OLYLQJVHYHUHSDLQZLWK
LQIODPPDWLRQ 
HU\WKHPDRUM RLQW
VZHOOLQJ±DQG
LQWHUIHULQJZLW K
DFWLYLWLHVRIG DLO\
OLYLQJSHUPDQHQWDQGRU
GLVDEOLQJMRLQW
GLVWUXFWLRQ 
0\DOJLD P\DOJLDZLWKQR
OLPLWDWLRQRIDFWLYLW\PXVFOHWHQGHUQHVV
DWRWKHUWK DQ
LQMHFWLRQVLWHRUZLWK
PRGHUDWHLPSDLUPHQWRIDFWLYLW\VHYHUHPXVFOH
WHQGHUQHVVZLWKPDUNHGLPSDLUPHQWRIDFWLYLW\
IUDQN
P\RQHFURVLV

6.,1
 *UDGH *UDGH *UDGH *UDGH
0XFRFXWDQHRXV HU\WKHPDSUXULWXV GLIIXVHPDFXOR
SDSXODUUDVKGU\
GHVTXDPDWL RQYHVLFXODWLRQRUPRLVW
GHVTXDPDWLR QRU
XOFHUDWLRQH[IROLDWLYHGHUPDWLWLV
PXFRXVPHPEUDQH
LQYROYHPHQW RU
HU\WKHPD
PXOWLIRUPHRU
VXVSHFWHG6WHYHQV
-RKQVRQRUQHFURVLV
UHTXLULQJVXUJHU\
,QGXUDWLRQ PP PP !PP 
(U\WKHPD PP PP !PP 
(GHPD PP PP !PP 
5DVKDW,QMHFWLRQ
6LWHPP PP !PP 
3UXULWXV VOLJKWLWFKLQJDW
LQMHFWLRQVLWHPRGHUDWHLWFKLQJDW
LQMHFWLRQH[WUHPLW\LWFKLQJRYHUHQWLUH
ERG\

Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 50
3URWRFRO3D&/9

7%$OOLDQFH &21),'(17,$/ 'HF
3DJH6<67(0,& 
 *UDGH *UDGH *UDGH *UDGH
$OOHUJLF5HDFWLRQ SUXULWXVZLWKRXWUDVK ORFDOL]HGXUWLFDULDJHQHUDOL]HGXUWLFDULD
DQJLRHGHPDDQDSK\OD[LV 
+HDGDFKH PLOGQRWUHDWPHQW
UHTXLUHGWUDQVLHQWPRGHUDWH
WUHDWPHQWUHTXLUHGVHYHUHUHVSRQGVWR
LQLWLDOQDUFRWLF
WKHUDS\LQWUDFWDEOHUHTXLUHV
UHSHDWHGQDUFRWLF
WKHUDS\
)HYHURUDO &RU
)&RU
)&RU
)!&RU! )
)DWLJXHQRUPDODF WLYLW\
UHGXFHGKRXUVQRUPDODFWLYLW\
GHFUHDVHG 
!KRXUVQRUPDODFWLYLW\
GHFUHDVHG!FDQ¶WZRUNXQDEOHWRFDUHIRU
VHOI


Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 51
3URWRFRO1XPEHU3D&/ 3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH 3DJH RI 'HF3URWRFRO&ODULILFDWLRQ/HWWHU
7%$OOLDQFH3URWRFRO3D&/$Q2SHQODEHO5DQGRPL]HG )RXUSHULRG&URVVRYHU
6WXG\LQ7ZR3DQHOVRI+HDOWK\$GXOW3DUWLFLSDQWVWR$VVHVVWKH 5HODWLYH%LRDYDLODELOLW\)RRG
(IIHFWDQG'RVHGHSHQGHQFHRI6LQJOH'RVH,PPHGLDWH5HOHDVHDQ G6LQJOHGRVH'LVSHUVLEOH
)RUPXODWLRQVRI3UHWRPDQLG
7KHSXUSRVHRIWKLVOHWWHULVWRFODULI\WKHWKDWUHWHQWLRQVDP SOHVDUHQRWQHHGHG
7KHVHFWLRQRISURWRFROYHUVLRQGDWHG'HFDIIHFWHG E\WKLVFKDQJHLVLQGLFDWHG
EHORZ
3URWRFRO3DJH6HFWLRQ'UXJ6XSSOLHV3DUDJUDSK
&XUUHQWO\UHDGV
6XIILFLHQWTXDQWLWLHVRIVWXG\GUXJZLOOEHVXSSOLHGWRDOORZI RUUHWHQWLRQVDPSOHV5HWHQWLRQ
VDPSOHVZLOOEHVWRUHGDWWKHFOLQLFDOVLWHSXUVXDQWWRWKHVLW H623V7KHVLWHZLOOEHUHVSRQVLEOH
IRUUDQGRPO\VHOHFWLQJGRVHVWREHDGPLQLVWHUHGDQGGRVHVWREH UHWDLQHG$WWKHFRQFOXVLRQRI
WKHVWXG\DQ\XQXVHGVWXG\GUXJQRWLQFOXGLQJUHWHQWLRQVDPSO HVZLOOEHUHWXUQHGWRWKH
VSRQVRURUGHVWUR\HGE\WKHVLWHSXUVXDQWWRZULWWHQDXWKRUL]DW LRQE\WKHVSRQVRUDQGDSSOLFDEOH
IHGHUDODQGVWDWHUHJXODWLRQV
5HYLVHGWRUHDG
5HWHQWLRQVDPSOHVRIWKHLQYHVWLJDWLRQDOVWXG\GUXJZLOOQRWEH UHTXLUHG$WWKHFRQFOXVLRQ
RIWKHVWXG\DQ\XQXVHGVWXG\GUXJZLOOEHUHWXUQHGWRWKHVSR QVRURUGHVWUR\HGE\WKHVLWH
SXUVXDQWWRZULWWHQDXWKRUL]DWLRQE\WKHVSRQVRUDQGDSSOLFDEOH IHGHUDODQGVWDWHUHJXODWLRQVGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 52
3URWRFRO1XPEHU3D&/ 3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH 3DJH RI 'HF$SSURYHG%\
6SRQVRU&RQWDFW )UDQFHV3DSSDV
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH 'DWH
0HGLFDO2IILFHU $QWRQLR7RQ\/RPEDUGL0'
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH 'DWH
3ULQFLSDO,QYHVWLJDWRU &\QWKLD$=DPRUD0'
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&1(/RRS6XLWH6DQ$QWRQLR7H[DV3KRQH
6LJQDWXUH 'DWH
 
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 53
3URWRFRO1XPEHU3D&/ 3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH 3DJH RI 'HF3URWRFRO&ODULILFDWLRQ/HWWHU
7%$OOLDQFH3URWRFRO3D&/$Q2SHQODEHO5DQGRPL]HG )RXUSHULRG&URVVRYHU
6WXG\LQ7ZR3DQHOVRI+HDOWK\$GXOW3DUWLFLSDQWVWR$VVHVVWKH 5HODWLYH%LRDYDLODELOLW\)RRG
(IIHFWDQG'RVHGHSHQGHQFHRI6LQJOH'RVH,PPHGLDWH5HOHDVHDQ G6LQJOHGRVH'LVSHUVLEOH
)RUPXODWLRQVRI3UHWRPDQLG
7KHSXUSRVHRIWKLVOHWWHULVWRFODULI\WZRH[FOXVLRQFULWHULD DQGDGGDWDVWHHYDOXDWLRQSRVWGRVH
7KHVHFWLRQRISURWRFROYHUVLRQGDWHG'HFDIIHFWHG E\WKLVFKDQJHLVLQGLFDWHG
EHORZ
3URWRFRO3DJH6HFWLRQ([FOXVLRQ
&XUUHQWO\UHDGV$FOLQLFDOO\VLJQLILFDQWDEQRUPDOILQGLQJRQWKHSK\VLFDOH[DPL QDWLRQPHGLFDOKLVWRU\
HOHFWURFDUGLRJUDP(&*RUFOLQLFDOODERUDWRU\UHVXOWV
5HYLVHGWRUHDG$FOLQLFDOO\VLJQLILFDQWDEQRUPDOILQGLQJRQWKHSK\VLFDOH[DPL QDWLRQPHGLFDOKLVWRU\
HOHFWURFDUGLRJUDP(&*RUFOLQLFDOODERUDWRU\UHVXOWV HJODERUDWRU\SURILOHVDUHQRUPDOXS
WRDQGLQFOXGLQJ*UDGHSHU'0,'WR[LFLW\WDEOHV
3URWRFRO3DJH6HFWLRQ([FOXVLRQ
&XUUHQWO\UHDGV
8VHRIDQ\RYHUWKHFRXQWHU27&PHGLFDWLRQLQFOXGLQJQXWULWL RQDORUGLHWDU\VXSSOHPHQWV
KHUEDOSUHSDUDWLRQVRUYLWDPLQVZLWKLQGD\VEHIRUHWKHILUV WGRVHRIVWXG\PHGLFDWLRQXQWLOWKH
HQGRIVWXG\YLVLWZLWKRXWHYDOXDWLRQDQGDSSURYDOE\WKH,QYHV WLJDWRU8SWRJUDPVSHUGD\RI
DFHWDPLQRSKHQLVDOORZHGDWWKHGLVFUHWLRQRIWKH,QYHVWLJDWRU SULRUWRGRVLQJ
5HYLVHGWRUHDG
8VHRIDQ\RYHUWKHFRXQWHU27&PHGLFDWLRQLQFOXGLQJQXWULWL RQDORUGLHWDU\VXSSOHPHQWV
KHUEDOSUHSDUDWLRQVRUYLWDPLQVZLWKLQGD\VEHIRUHWKHILUV WGRVHRIVWXG\PHGLFDWLRQXQWLOWKH
HQGRIVWXG\YLVLWZLWKRXWHYDOXDWLRQDQGDSSURYDOE\WKH,QYHV WLJDWRU2FFDVLRQDOXVHRI XSWR
JUDPVSHUGD\RIDFHWDPLQRSKHQLVDOORZHGDWWKHGLVFUHWLRQR IWKH,QYHVWLJDWRUSULRUWRGRVLQJ
3URWRFRO3DJH6HFWLRQ7DEOH6FKHGXOHRI$VVHVVPHQWVD QG3URFHGXUHV
$GG³7DVWHHYDOXDWLRQK´WR7DEOHZLWKWKHIROORZLQJIRRWQRWH
K7DVWHHYDOXDWLRQZLOOEHFRQGXFWHGLPPHGLDWHO\DIWHUGRVLQJD QGPLQXWHVDIWHU
DGPLQLVWUDWLRQWRGHWHUPLQHDQ\DIWHUWDVWHGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 54
3URWRFRO1XPEHU3D&/ 3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH 3DJH RI 'HF$SSURYHG%\
6SRQVRU&RQWDFW )UDQFHV3DSSDV
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH 'DWH
0HGLFDO2IILFHU $QWRQLR7RQ\/RPEDUGL0'
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH 'DWH
3ULQFLSDO,QYHVWLJDWRU &\QWKLD$=DPRUD0'
:RUOGZLGH &OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&
1(/RRS6XLWH
6DQ$QWRQLR7H[DV3KRQH
6LJQDWXUH 'DWH
 
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 55
3URWRFRO1XPEHU3D&/ 3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH 3DJH RI -DQ3URWRFRO&ODULILFDWLRQ/HWWHU
7%$OOLDQFH3URWRFRO3D&/$Q2SHQODEHO5DQGRPL]HG )RXUSHULRG&URVVRYHU
6WXG\LQ7ZR3DQHOVRI+HDOWK\$GXOW3DUWLFLSDQWVWR$VVHVVWKH 5HODWLYH%LRDYDLODELOLW\)RRG
(IIHFWDQG'RVHGHSHQGHQFHRI6LQJOH'RVH,PPHGLDWH5HOHDVHDQ G6LQJOHGRVH'LVSHUVLEOH
)RUPXODWLRQVRI3UHWRPDQLG
7KHSXUSRVHRIWKLVOHWWHULVWRXSGDWHWKHFRQWDFWLQIRUPDWLRQ IRUVHULRXVDGYHUVHHYHQW6$(
UHSRUWLQJ7KHVHFWLRQRISURWRFROYHUVLRQGDWHG'HF DIIHFWHGE\WKLVFKDQJHLV
LQGLFDWHGEHORZ
3URWRFRO3DJH6HFWLRQ6HULRXV$GYHUVH(YHQW5HSRUWLQJ 
&XUUHQWO\UHDGV
33'39*SKDUPDFRYLJLODQFHVHUYLFHSURYLGHUIRU7%$OOLDQFH
(PDLOUWSVDIHW\#SSGLFRP
6DIHW\+RWOLQH
6DIHW\)D[1XPEHU
$QG$QWRQLR7RQ\/RPEDUGL0'
*OREDO$OOLDQFHIRU7%'UXJ'HYHORSPHQW
:DOO6WUHHWWK)ORRU1HZ<RUN1<8QLWHG6WDWHVRI$PHULFD7HOHSKRQH0RELOH)DFVLPLOH(PDLO$QWRQLR/RPEDUGL&RQVXOWDQW#WEDOOLDQFHRUJ
5HYLVHGWRUHDG
7%$OOLDQFH3KDUPDFRYLJLODQFH
(PDLO$(BLQER[#WEDOOLDQFHRUJ
4XHVWLRQVUHODWLYHWR6$(FDVHSURFHVVLQJPD\DOVREHVHQWWRW KHDERYHPHQWLRQHGHPDLO
DGGUHVV,IWKHUHLVHYHUDQHPDLOIDLOXUHXSRQWU\LQJWRUHSRU WDQ6$(SOHDVHFDOO
'U/RPEDUGLDWDQGKHZLOOQRWLI\WKH6DIHW\WH DPDW7%$OOLDQFH
0HGLFDOTXHVWLRQVUHODWLYHWR$(VRU6$(VFDQEHGLUHFWHGWR
$QWRQLR7RQ\/RPEDUGL0'*OREDO$OOLDQFHIRU7%'UXJ'HYHORSPHQW:DOO6WUHHWWK)ORRU1HZ<RUN1<8QLWHG6WDWHVRI$PHULFD7HOHSKRQH
0RELOH
)DFVLPLOH(PDLO$QWRQLR/RPEDUGL&RQVXOWDQW#WEDOOLDQFHRUJGlobal Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 56
3URWRFRO1XPEHU3D&/ 3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH 3DJH RI -DQ$SSURYHG%\
6SRQVRU&RQWDFW )UDQFHV3DSSDV
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH 'DWH
0HGLFDO2IILFHU $QWRQLR7RQ\/RPEDUGL0'
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH 'DWH
3ULQFLSDO,QYHVWLJDWRU &\QWKLD$=DPRUD0'
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&1(/RRS6XLWH6DQ$QWRQLR7H[DV3KRQH
6LJQDWXUH 'DWH
 
		


	Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 57